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ABSTRACT OF DISSERTATION

Probing the Assembly, Functional Relevance, and Dynamics of AcrA in Multi Drug
Efflux in Escherichia. coli
Efflux pumps and low permeability of the outer membrane of gram-negative
bacteria are major culprits in drug resistance. The most studied of these multidrug efflux
pumps is the AcrAB-TolC, a complex of three proteins, the inner membrane
transporter AcrB, the periplasmic adaptor AcrA and outer membrane factor TolC. This
pump exports a wide range of molecules such as dyes, detergents, and antibiotics out of
the bacteria system into the external environment. AcrB and TolC exist as obligate trimers,
but the structure of AcrA during the assembly process is not well defined. My research
aims to explore the functional and structural dynamics of the AcrAB-TolC pump to target
the efflux pumps for effective antibiotic development. To achieve this, it is important to
understand its structure, behavior, and function within the cell. The dominant negative
effect of inactive AcrA and AcrB mutants was investigated, and we proved that once
formed, the complex remains bound and does not dissociate easily. We also speculated that
the
assembly
of
the AcrAB-TolC is
a precisely controlled
process
involving delicate proof-reading mechanisms that prevent the formation of futile complex.
I explored the role of the unresolved N-and C-terminal ends (NT and CT) in the
function and activity of AcrA. At the NT, we removed residues Q31QGG34 resulting in loss
of activity. We found that upon replacement of the signal peptide of AcrA with that of
OmpA, function of this mutant was restored. The removal of residues 26-37 resulted in a
significant loss of AcrA activity even with the OmpA signal peptide. We also found that
the CT unresolved residues were not important for the function of AcrA. At the C terminus,
truncation of the last 20 residues from E377 to 397 had no detectable impact on activity
until lysine at position 374 (K374) when the protein became fully inactive.
Disulfide trapping was also used to probe the structure and conformation of AcrA
oligomers in E. coli cells, and the interaction of AcrA and AcrB. Sites were chosen based
on the tip-to-tip model from the cryo-EM AcrABZ-TolC complex structure and were used
as probes to examine factors that affects the hexameric structure of AcrA, that is if the
presence of AcrB or TolC affects oligomer formation. We speculate that formation of inter
molecular disulfide links between AcrA and AcrB, and between neighboring AcrA

subunits, would indicate that the tip-to-tip model truly reflect the assembled structure of
the complex in bacteria cells. This is important since most supporting evidence for the tipto-tip model comes from cryo-EM studies using purified proteins.
KEYWORDS: Efflux Pump, AcrAB-TolC, Dominant Negative, Pump Assembly,
Disulfide Crosslinking, Tip-to-Tip Model
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CHAPTER 1. INTRODUCTION
1.1

Antibiotics: History, Discovery, and Development
Preceding the start of the 20th Century, infectious diseases was responsible for high

morbidity and mortality worldwide1. The average life expectancy at birth was very low
even in the industrially developed societies. Infectious diseases like smallpox, cholera,
diphtheria, pneumonia, typhoid fever, plaque, tuberculosis, typhus, syphilis, etc. were
widespread.
Antibiotics has contributed tremendously to the saving of millions of lives all over
the world. Conflicting with popular belief that the exposure to antibiotics is confined to the
modern “antibiotic era,” research has uncovered that this is not the case2. The traces of
tetracycline, for example, have been observed in human skeletal remains from ancient
Sudanese Nubia dating back to 350–550 CE3, 4. The distribution of tetracycline in bones is
only rational after exposure to tetracycline-containing materials in the diet of these ancient
people. Histological evaluation of samples from femoral midshafts of the late Roman
period skeletons from the Dakhleh oasis in Egypt provides another excellent instance of
ancient exposure to antibiotics5, 6. Curative remedies used in traditional / alternative
medicine was a pointer to antibiotic exposure in pre-antibiotic era. For example in
traditional Chinese medicine, it was discovered that qinghaosu (artemisinin), which was
extracted from Artemisia plants, used by Chinese herbalists for thousands of years as a
medication for many illnesses exhibited antimicrobial property7.
1

Alexander Fleming’s discovery of penicillin in 1928 sparked the start of the antibiotic
revolution. Although penicillin became widely available aside the Allied military in 19458,
Howard Florey and Ernst Chain were first to purify penicillin G in 1942 signaling the
beginning of the era of antibiotics. The 1950s and 1970s were regarded as the ‘golden era’
of new antibiotics discovery. The market witnessed a surge in introduction of new
antibiotics with over 100 antibiotics making its way into it because of the fast-paced
characterization of compounds with antimicrobial properties. The ensuing significant
antibiotic discovery was the sulfonamide groups. In 1943 aminoglycosides streptomycin
was discovered which most produced by fermentation except for chloramphenicol which
was synthesized. Unfortunately, there is a dart in the discovery of new classes of
antibiotics, as efforts in discovery changed course into the modification of already existing
ones2.

Figure 1.1 Antibiotic discovery and associated development of antibiotic resistance9.
(Reprinted with permission from publisher. Copyright ©2010, American Society of
Microbiology)
2

1.2

Antibiotic Classes and Mechanism of Action

Antibiotics can be grouped into two classes because of their mechanism of action.
Bactericidal antibiotics kill bacteria; bacteriostatic antibiotics inhibit their growth or
reproduction10. The table below gives a snapshot of antibiotic class and their modes of
action.

Table 1.1 Classes of antibiotics and their mode of action

Antibiotic class

Example(s)

Target

Β-Lactams

Penicillins
(ampicillin),
cephalosporins,
(cephamycin),
penems
(meropenem),
monobactams
(aztreonam)
Gentamicin,
streptomycin,
spectinomycin

Peptidoglycan
biosynthesis

Translation

Phosphorylation,
acetylation,
nucleotidylation,
efflux, altered target

Tetracyclines

Minocycline,
tigecycline

Translation

Monooxygenation,
efflux, altered target

Macrolides

Erythromycin,
azithromicin

Translation

Hydrolysis,
glycosylation,
phosphorylation,
efflux, altered target

Lincosamides

Clindamycin

Translation

Nucleotidylation,
efflux, altered target

Β-Lactams

Penicillins
(ampicillin),
cephalosporins,
(cephamycin),
penems

Peptidoglycan
biosynthesis

Hydrolysis, efflux,
altered target

Aminoglycosides

3

Mode(s) of
resistance
Hydrolysis, efflux,
altered target

Table 1.1
(continued)
Gentamicin,
streptomycin,
spectinomycin

Translation

Phosphorylation,
acetylation,
nucleotidylation,
efflux, altered target

Tetracyclines

Minocycline,
tigecycline

Translation

Monooxygenation,
efflux, altered target

Macrolides

Erythromycin,
azithromicin

Translation

Hydrolysis,
glycosylation,
phosphorylation,
efflux, altered target

Lincosamides

Clindamycin

Translation

Nucleotidylation,
efflux, altered target

Streptogramins

Synercid

Translation

C-O lyase (type B
streptogramins),
acetylation (type A
streptogramins),
efflux, altered target

Oxazolidinones

Linezolid

Translation

Efflux, altered target

Phenicols

Chloramphenicol

Translation

Acetylation, efflux,
altered target

Quinolones

Ciprofloxacin

DNA replication

Acetylation, efflux,
altered target

Pyrimidines

Trimethoprim

C1 metabolism

Efflux, altered target

Sulfonamides

Sulfamethoxazole

C1 metabolism

Efflux, altered target

Rifamycins

Rifampin

Transcription

ADP-ribosylation,
efflux, altered target

Lipopeptides

Daptomycin

Cationic peptides

Colistin

Aminoglycosides

Cell membrane
Cell membrane

Altered target
Altered target, efflux

Adapted from reference 11 with permission of the publisher, © 2010 Annual Review Genetics
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1.3

Antibiotic Resistance in Gram Negative Bacteria
Many of the bacterial pathogens associated with outbreaks of human diseases have

developed into multidrug-resistant (MDR) forms after antibiotic use9. For example, MDR
M. tuberculosis is a major pathogen found in both developed and non-industrialized
societies and became the 20th-century version of an old pathogen. The word “superbugs”
refer to microbes with increased morbidity and mortality due to multiple mutations
conferring high levels of resistance to the antibiotic classes specific for their treatment9.
The development of resistant strains is a natural occurrence because of selection pressure
from the antibiotic on the microorganism population. The use and misuse of antimicrobial
drugs exacerbates the emergence of drug-resistant strains. Bacterial antibiotic resistance is
a well-recognized challenge. It is a major threat to human welfare and the leading problem
in the effort to curtail infectious diseases12. The spread of drug resistant pathogen leads to
dreadful outcomes. There are increasing numbers of microorganisms developing the ability
to withstand antibiotics at rates that have never been seen before. Standard treatments
become insufficient, and infection persists with the risk of spread of infections to healthy
people13.
Louis B. Rice originally invented, the word “ESKAPE pathogens”, and was
subsequently recognized by World Health Organization (WHO). They are described as a
‘group of deadly bacterial pathogens with rapidly growing multidrug resistant properties’1416

. This include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,

Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These bugs
were selected because of their rate of infection, mortality, occurrence of resistance, and
availability of treatment options17. Four out of the six pathogens are Gram negative

5

bacteria. In addition, in 2017 WHO published a list of 12 pathogens classified in critical,
high, and medium crisis. The critical category contains three bacteria, all of which are gram
negative while nine out of the 12 pathogens are gram-negative.18
According to the Centers for Disease Control and Prevention (CDC) and World
Health Organization (WHO), close to 2.8 million people are infected with antibioticresistant bacteria or fungi, with more than 35,000 people dying each year in the United
States18 19.
Antibiotic resistance can essentially be expressed by four different mechanisms13.

1.3.1

Mechanism of Antibiotic Resistance

There are four different mechanisms by which bacteria become resistant to antibiotics as
described below:
A. Prevention of penetration into the cells: Antibiotics must be able to penetrate the
bacteria cytoplasmic membrane (inner membrane) and outer membrane to be efficient
against their targets which are usually intracellular or in the cytoplasm in the case of
gram-negative bacteria20,

21

. Amongst the first means of bacterial defense against

antibiotics and other toxic molecules usually is the outer membrane which has a low
permeability, thereby reducing the entry of antibiotics into the cell and thus reducing
efficiency.
B. Expulsion via efflux pump: Studies have shown the presence of transmembrane protein
complexes in the bacteria membrane that transport a variety of molecules out of the
bacteria cell 22. This mechanism reduces the drug concentration within the bacterial cell,
and thus the effectiveness of the antibiotics. These molecules include but not limited to

6

beta-lactam, fluoroquinolones, carbapenems and polymyxins. The genes that encodes
the efflux pumps can be in the mobile genetic elements such as the plasmids,
transposons etc. or in the chromosomes23.

C. Modification or degradation of antibiotics: Resistance to antibiotics could result from
destruction or chemical alteration of the molecule. Antibiotics that exert their function
on the ribosomes are usually mostly affected by these alterations20. These enzymes
modify the amino and hydroxyl groups of the aminoglycosides such as in acetylation
(acetyltransferases), phosphorylation (phosphotransferase) and adenylation (adenyl
transferases). Resistance to antibiotics that have the beta lactam ring in their structure
such as the penicillin derivatives, penams, cephalosporins, carbapenems etc. typically
have their amide bond destroyed by the beta lactamase enzyme making the antibiotics
ineffective and thus enhance resistance of bacteria to these drugs 24.

D. Modification of the target: A case of the target protection mechanism is the tetracycline
resistance determinants Tet(M) and Tet(O). Tet (M) changes the ribosomal
conformation, preventing rebinding of the antimicrobial25. TetO compete with
tetracycline for the same ribosomal space and remove the molecule from the ribosome
and letting protein synthesis to continue26. Resistance to penicillin is caused by altering
the penicillin binding proteins that form complexes with penicillin thereby preventing
its role in synthesis of peptidoglycan.
E. Genetic basis: The genes for bacteria resistance can be spread from one bacterium to
another by plasmids, bacteriophages, naked DNA, or transposons. Bacteria can acquire

7

genes involved in mutation which affects the action of the antibiotics through one of the
mechanisms already mentioned above. Horizontal gene transfer also come into play; the
simplest mode of this is by transformation a process whereby bacteria can internalize
genetic material.

Figure 1.2 Targets, Mechanisms, and acquisition of Antibiotic Resistance.

This figure belongs to 13 . © Authors. Publisher: Angew. Chem. Int. Ed. 2016
License link: https://creativecommons.org/licenses/by-nc-nd/4.0/
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1.4

Roles of Efflux Pumps in Multidrug Resistance in Bacteria
Efflux pumps play a crucial role in conferring multidrug resistance in bacteria by

transporting antibiotics from the cell. These proteins are found in both gram-positive
and gram-negative bacteria as well as in eukaryotic organisms27. By virtue of their
composition, number of transmembrane spanning regions, source of energy and
substrates they bind, bacterial efflux pumps are categorized into five families: MF
(major facilitator), MATE (multidrug and toxic efflux), RND (resistance-nodulationdivision), SMR (small multidrug resistance) and ABC (ATP binding cassette)

28 23, 29

(Figure 1.2). RND family are found in gram-negative bacteria only, whereas the four
other families are found in both gram negative and gram-positive bacteria30. All the
efflux system listed utilizes the proton motive force as a source of energy except for the
ABC system that uses the hydrolysis of ATP to export substrates out of the cell 31. These
efflux pumps are either single-component transporters or multi-component which
contains the inner membrane transporter, the periplasmic adaptor protein and outer
membrane channel. Due to the tripartite nature of the pump, extrusion out of the
cytoplasm and periplasm into the external medium is facilitated32. The members of the
RND family form a tripartite complex spanning across the two membranes of Gramnegative bacteria 33. RND family proteins have been found to be involved with clinically
significant antibiotic resistance, such as AcrB in Escherichia coli and Salmonella
typhimurium and MexB in Pseudomonas aeruginosa. The efflux pumps in gram
positive bacteria that are clinically important are members of the MFS family, for
example NorA in Staphylococcus aureus and PmrA in Streptococcus pneumoniae 34. Of
great concern is the diverse range of substrates of the efflux system because

9

overexpression of the efflux pump usually leads to resistance to more than one antibiotic
as well as some detergents, disinfectants, and dyes

35

. For example, P. aeruginosa

mutants that over produces MexAB are very resistant to diverse antibiotics such as the
lactams, fluoroquinolones, and chloramphenicol and to the home-used biocide, triclosan
36

.
With advancements in the resolution of crystal structures, molecular dynamics (MD)

simulation has become a useful tool for studying and understanding the molecular and
functional mechanisms of bacteria efflux pumps. This computational method was first
developed and utilized in the 70s37, 38 and has evolved from use for simulating hundreds
of atoms to systems with biological importance such as protein in solution, membranebound proteins, or ribosomes39-41.
In recent times, efflux pump inhibitors have been exploited to potentiate the activity
of antibiotics. Strategy as such has been used to develop inhibitors capable of reducing
the effect of efflux pumps on fluoroquinolone activity 42. These efflux pumps have been
found to play several physiological roles including bacteria pathogenicity and virulence,

10

cell

to

cell

communication

and

in

biofilm

formation.43

Figure 1.3 Representations of the five families of efflux pumps 44.
Resistance nodulation division (RND), small molecule resistance (SMR), ATP binding
cassette (ABC), Multidrug and toxic compound extrusion (MATE) and Major facilitator
superfamily (MFS)
Reprinted with permission from publisher © 2018, Springer Nature

1.5

AcrAB-TolC Efflux Pump in Bacteria Resistance
A member of the well-studied RND super family efflux pump, AcrA-AcrB-TolC is

a tripartite complex that spans the bacteria double membraned barrier. It is a complex of
the periplasmic adaptor protein (PAP) AcrA, the inner membrane drug/proton antiporter
AcrB, and the outer membrane (OMF) TolC, all working together to transport substrate
through the periplasm out of the bacteria system33, 45. Upon binding of substrate, AcrB uses
the energy from the proton-motive-force derived from substrate/proton antiport to drive
the transport of substrate into the periplasm46, 47, from where AcrA serving as a bridge
between the inner and outer membranes48, 49, undergoes conformational change to move
11

the substrate into the outer membrane compartment TolC. TolC is shared by several RND
family efflux systems for exports of substrate into the extracellular environment50, 51. AcrA
and other MFP homologs have been suggested to recognize substrate-dependent changes
in conformation in the transporter and to interact with substrates directly, allowing
engagement of the outer membrane (OM) channel into the trans envelope complex

52

.

Interaction with the outer membrane channel activate the assembly of the AcrA tunnel and
the conformational changes in AcrA required to stimulate the transporter and open the OM
channel 52. In free form AcrA exists as a dimer or trimer but in the assembled complex, it
forms a hexameric barrel through the trimerization of the dimers that are distinct in
conformation 53 with one protomer suggested to interact with TolC, the other is involved
with interaction with AcrB like stimulation of the turn-over of transporter 48.

Figure 1.4 Structures of the proteins in the tripartite AcrAB-TolC efflux system.
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AcrB (PDB: 1IWG, 2GIF) is in the inner membrane (IM) and is composed of the
transmembrane domain, the porter (pore) domain and the TolC docking domain. TolC is
resident in the outer membrane (OM) with its β-barrel domain and forms a long tube in the
periplasm by its α-helical domain. AcrA (2F1M) is divided into the -barrel domain, the
lipoyl domain and the α-helical hairpin. Its N-and C-termini are not assigned due to missing
electron density. AcrA is connected to the inner membrane through its N-terminal lipid
anchor
Adapted from54 with permission from publisher © Current Drug Target, 2008

1.5.1

Acriflavine Resistance Protein A (AcrA)

AcrA and other MFPs have four domains that are arranged in a linear fashion: The
alpha helical hairpin is the docking site for TolC; the lipoyl domain’s role is to stabilize the
complex; the alpha-beta barrel domain binds to ligands such as Zinc ion; and the membrane
proximal domain is usually not structured and can easily be digested by protease 55. The
other domains interact with AcrB, while the α hairpin docks to TolC42, 51, 56, 57. AcrA can
undergo large-scale conformational changes because of its flexibility. Mutational studies
have shown that deletion of the gene locus of AcrA led to the total abrogation of the activity
of the efflux pump, further reinforcing the functional relevance of AcrA58, 59. AcrA or
other PAPs are attached to the membrane through an acylated cysteine residue at position
25 or via a transmembrane helix at the N terminus. This attachment to the membrane is not
relevant to the efflux function because even when the attachment is removed, the soluble
AcrA retains its activity49. The use of computational methods to simulate AcrA based on
high resolution of its structure have improved our understanding of the intramolecular
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interaction within the domains and intermolecular contacts between AcrA and other pump
components.53, 60, 61.

Figure 1.5 Structure of AcrA developed from pymol and linear cartoon representation:
AcrA has four domains, the α-helical hairpin, lipoyl, β-barrel and the membrane proximal
domains.

1.5.2

Acriflavine Resistance Protein B (AcrB)

The symmetric, and asymmetric crystal structures of AcrB protein in the apo and
substrate bound states have been determined through various studies62-68. AcrB functions
as a homotrimer, with each subunit containing 12 transmembrane α-helices which makes
14

up the transmembrane domain (TMD). It has another domain called the periplasmic
domain53. The TMD is important in proton transport and thus energy production through
proton motive force. Periplasmic domain which has porter domain, and the funnel/docking
domain functions in substrate recognition and binds to the specific drug binding pockets.
Previous studies have indicated there are several drug binding sites located in the AcrB
(central cavity, periplasmic site) This facilitates the broad range of recognition and binding
capability of AcrB transporter thereby allowing the expulsion of drug through efflux69.
AcrB porter domain further divides into four major subdomains known as PN1, PN2, PC1,
and PC2. Subdomains PN1 and PN2 are in the N terminal between transmembrane helices
TMH1 and TMH2 while PC1 and PC2 are located between the TMH7 and H8 in the C
terminal. These subdomains have significant roles in the drug transport mechanism.
Furthermore, PN1 and PC2; PN2 and PC1 subdomains together form a rigid β- sheet
structure forming two structural subunits called PN1-PC2 and PN2-PC1. The funnel
domain has two major subdomains, DC and DN70-73.
1.5.3

Functional Rotation Mechanism of AcrB

The structural asymmetry of the AcrB transporter allows three conformations in
each protomer representing different stages of the drug transport cycle. These 3 different
stages are termed as access (Loose-L), drug binding (Tight-T) and drug extrusion (OpenO) cycles64,

74-76

. These have high structural homogeneity and protomers exhibit

characteristic protonation states in the transmembrane domain77. The conformational
changes that each protomer undergoes was explained by the peristaltic functional rotation
mechanism60,

64, 74-76, 78, 79

. Functional rotation mechanism proposes that in the access

conformation, the open and close activity of the external cleft between the PC1 and PC2
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subdomains changes the distances between the protomers at the periplasmic domain.
Therefore, substrates bind to access pocket/ periplasmic binding pocket (AP/ PBP) at the
first stage. In the binding conformation, the cleft opens wide whereas in the extrusion
conformation, movement of the PC1 and PC2 subdomains caused the closure of PC2.
Substrates that entered to AP/PBP move to DP/DBP during the transition from binding to
extrusion. Thereafter, due to the movement of DBP substrate is expelled to the central
funnel in TolC. The proton translocation across the transmembrane domain and drug
binding to the porter domain initiate these conformational changes64. The new cryo-EM
model study showed that ligand binding is allosterically coupled with the channel-opening.
The channel remains open through drug transport cycle, thus showing a dynamic
mechanism of efflux53.

Figure 1.6 Structure of AcrB with functional rotation mechanism A. AcrB structure B.
AcrB subdomains C. Illustration of the functional rotation mechanism of AcrB showing 3
different stages are termed as open access (Loose-L), drug binding (Tight-T) and drug
extrusion (Open-O).
16

1.5.4 Tolerance to Colicin (TolC)
TolC is a 493 amino acids outer membrane protein (OMP) of the AcrAB-TolC
complex. It is the channel for the expulsion of the molecules, toxins, and drugs from the
cell into the external environment. TolC in E. coli is shared by many different biological
efflux complexes or processes in the cell. It has a tube shape with a tight constriction at
the periplasmic end. It is a 140 Å protein with two domains; the outer membrane 40 Å
β-barrel domain and the periplasmic 100 Å α-helical domain

72

. It forms trimer with

periplasmic helical barrel, transmembrane barrel, and folds in the periplasm80, 81. In the
outer membrane, it is opened to the extracellular environment, but it remains closed at
the periplasmic end until a complex recruit it for assembly. Once recruited, it then
translocate the molecules into the external environment82. TolC consisting of protomers
with structural repeats, forms a six folds symmetry.

1.5.5

The Deep Interpenetration and the Tip-to-Tip Models of Pump Assembly
Two models of the assembled structure of the entire AcrAB-TolC complex have

been proposed, each based on convincing experimental results. However, the dynamic
process leading to the formation of the delicate molecular machinery remains elusive. AcrB
and TolC exist as independent trimers in the inner and outer membranes, respectively, but
the cellular structure of AcrA is not as well defined. Being the adaptor between the inner
and outer membrane component, AcrA is expected to be more flexible and may undergo
large scale conformational change during the complex assembly.
The first fully assembled model called the ‘deep interpenetration’ model was
proposed in 2004, using the crystal structures of AcrB, TolC, and MexA based on
17

experimental data available at the time82-84. It proposes a direct interaction between AcrB
and TolC with AcrA wrapped around on the outside to stabilize the complex85. Each
individual hairpin docks into separate grooves on the OMF surface. The more recent ‘tipto-tip’ model was based on the cryo-EM structure of the complex by Wang et.al,

12

. It

suggests that the AcrA hairpins forms hexameric barrel, making contacts with TolC α-helix
only in a tip-to-tip fashion. The recent determination of the complex structure first by cryoEM, then by X-ray crystallography, proved and confirmed the tip-to-tip model63, 65, 66, 76, 8688

.

Figure 1.7 Models of AcrAB-TolC interaction. The “deep-interpenetration” models (left)
and the “tip-to-tip” models (right) based on the experimental cryo-EM structures of
AcrABZ-TolC (pdb: 5O66).
Adapted from89 © 2020 Marshall and Bavro, Frontiers in Molecular Biosciences
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1.5.6

Disulfide Bonds in the Study of Membrane Protein

Proteins are key players and executors of life90, 91. Most physiological processes in
living cells involve concerted effort of many small and macro molecules including proteins,
that form transient or permanent interactions and undergo dynamic structural changes92.
Protein−protein interactions facilitate arguably all cellular functions such as transcription,
translation, biogenesis, metabolism, cell signaling, and cell differentiation93-95. Traditional
methods of studying the interactions of proteins or identifying components of complexes
have involved disruption and extraction of proteins from cells, followed by
chromatographic separation steps and protein identification using immunoblotting, mass
spectrometer or other methods

96, 97

. Such practices may lead to the dissociation of

complexes with low affinity. This is especially true for membrane proteins, as their
extraction from the cell membrane normally involves the solubilization using high
concentrations of detergent to replace the lipid molecules. Potential impact on analysis are
two facets. First, detergent molecules are not good mimics of lipids, and thus the behavior
of membrane proteins in a detergent-solubilized state could be very different from the lipidimbedded stage 98, 99. Second, the use of high concentration of detergent leads to a dilution
effect to the concentration of monomers or subunit which could lead to dissociation100.
Hence the need for a more robust method to capture and study membrane proteins becomes
invaluable.
In the 1960s, Anfinsen and coworkers through their work on bovine pancreatic
ribonuclease (RNAse) provided a pioneering insight into disulfide bond formation. They
demonstrated the renaturation of the RNAse in the presence of oxygen to native
biologically active enzyme in vitro after the disulfide bond was initially reduced and the
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tertiary structure disrupted101. This proved that the restoration of the native conformation
of a purified protein can occur in a test tube without cofactors or helper enzymes,
culminating in the conclusion that information encoded within the amino acid is enough
prerequisite for accurate formation of disulfide bond and folding of the molecule. Bovine
pancreatic RNAse is a secreted protein comprising of 8 cysteine residues that produces 4
disulfide bonds. It was reported that since there are 700 possible cysteine connectivity in
the RNAse and dithiothreitol is needed for reduction, the rate-limiting step of assembly
requires accurate formation of an array of disulfide bonds102. The protein folding in vitro
was found to occur at a much shorter time as would normally be expected for efficient cell
growth. The discovery of the first protein folding catalyst, called protein disulfide
isomerase (PDI) stems from this proposal103

104, 105

. It efficiently mediates the

rearrangement of disulfides that are not formed correctly102 . Through this work, Anfinsen
et al reportedly linked the budding field of molecular biology with that of the wellestablished protein chemistry, drawing the attention of scientists in both fields into
unraveling the mechanism of protein folding106.
A very important step in protein folding is the formation of disulfide bond between
thiol groups of cysteine residues107. In bacteria, disulfide bond is absent in cytoplasmic
proteins, due to the reducing environment of the cytoplasm. Disulfide bond forms in the
periplasm, in periplasmic proteins or periplasmic domains of membrane proteins108, where
a set of enzymes act on catalyzing its production and correction. 109, 110. The disulfide bond
formation mechanism in E. coli is facilitated by the Dsb enzyme system111,

112

. Two

pathways exist for the formation of disulfide bonds in E. coli. The oxidation pathway
catalyzed majorly by DsbA/DsbB and the isomerization/reduction pathway by DsbC and
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DsbD113, 114. DsbA has the thioredoxin fold, the redox-active site CxxC and a cis-Pro motif
for interaction with substrate115, 116. When DsbA catalyzes the disulfide formation in a
substrate protein, it becomes reduced and must be re-oxidized by DsbB bound in the inner
membrane (IM) to continue its oxidative function117. Re-oxidation of DsbA involves the
transfer of electrons by DsbB to quinones as electron acceptors in the respiratory chain
network and eventually to oxygen

118, 119

. In the isomerization/reduction pathway,

misfolded proteins due to mis-oxidation are returned to its correctly folded disulfidebonded state. DsbC doubles as a thiol-disulfide bond isomerase and a chaperone to catalyze
this step. The misfolded protein can also be destroyed by proteases in the periplasm111, 120.
DsbC is kept in a reduced form by DsbD in the cytoplasmic space by using the
thioredoxin/thioredoxin reductase system in the cytosol as a source of reducing
equivalents121-123.
The dynamic, structural, and functional landscapes of both soluble and membrane
proteins have been revealed through site-directed cysteine and disulfide chemistry 124. This
is followed by down-stream manipulations including protein purifications and protease
digestion

125,

126

. Detection methods include gel electrophoresis, fluorescence

measurement, and mass spectrometry-based techniques127
Disulfide cross-links have been used very extensively to study the structural
dynamics and other properties of the tripartite efflux pump AcrAB-TolC involved in multi
drug resistance, which showcased the versatility of the method

16, 41, 74, 75, 128, 129

.

Interestingly, the cryo-electron microscopy structure of the AcrABZ-TolC complex was
obtained by Wang et al using a disulfide bond stabilized complex, formed between residues
S273 of AcrA and S258 of AcrB (AcrA S273C-AcrB S258C)53. A stable tripartite complex
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in the cell was formed as the disulfide linked AcrAB recruited TolC, and the complex
survived detergent solubilization and purification strategy. Tamura et al studied the direct
interaction between TolC and AcrB through the formation of in vivo disulfide cross-links
between the two proteins130. They introduced cysteine at the interfaces of AcrB and TolC
as depicted from their structures using site directed mutagenesis (SDM) to generate
disulfide bonded AcrB-TolC spontaneously. This further showed that the cysteine residue
in AcrB is near to TolC, thus supporting the proposed docking model of interaction
between both proteins65. They introduced cysteine mutations by combining two plasmids,
one that expresses histidine tagged TolC and one with cysteineless AcrB, in which natural
cysteine was removed. Both plasmids were transformed into a hypersensitive E. coli strain.
The mutants retained their efflux activity. The positions of the disulfide bonds were around
the hairpins of AcrB and TolC. The authors noted that formation of AcrB-TolC complex
was not sensitive to the presence or absence of substrates or to AcrB protonation.
In this study we chose and tested sites that according to the ‘tip-to-tip’ structure
model of the AcrAB-TolC complex, disulfide bond should form, and we examined their
impact on efflux activity.
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Figure 1.8 Disulfide oxidation and isomerization in the periplasm of E. coli. DsbB obtains
its oxidizing materials from a quinone cofactor. It uses these materials to reoxidize DsbA.
Through thiol-disulfide exchange, DsbA oxidized protein substrate. DsbC which is reduced
by DsbD, rearranges the disulfide bonds. DsbD is reduced and maintained in a reduced
state by thioredoxin in the cytoplasmic compartment.
Adapted from 107 and reprinted with permission from Elsevier.
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CHAPTER 2. INSIGHT INTO ACRAB ASSEMBLY PROCESS LEARNED FROM
COMPETITION STUDIES

Reproduced in parts from Antibiotics 2021, 10, 830 with permission from publisher,
MDPI 2021131.
2.1

Introduction
Antimicrobial resistance, especially multidrug resistance in bacterial pathogens, is

among the top 10 global threats to humanity132. Among the large array of different defense
mechanisms adapted by bacteria, the overexpression of efflux pumps has a significant role
in conferring multidrug resistance. AcrAB-TolC is one of the most extensively studied
efflux pump systems in Gram-negative bacteria, playing a crucial role in the multidrug
resistance in bacteria such as Escherichia coli

33, 45, 133

. AcrAB-TolC is a member of the

resistance nodulation division (RND) superfamily. AcrAB-TolC efflux pump confers
resistance to a broad spectrum of antimicrobial compounds including β-lactams,
tetracycline, novobiocin, and fluroquinolones
consists of three major protein components

72, 134

82, 86

. This tripartite efflux transporter

, an outer membrane channel TolC, a

periplasmic adaptor protein (PAP) AcrA, and an inner membrane proton-driven antiporter
AcrB 70, 80, 135, 136. TolC forms a channel that spans the outer membrane and acts as the exit
pathway of substrates translocated from the inner membrane and the periplasmic space.
AcrA has function in stabilizing the connection between the two membrane components
TolC and AcrB

48, 49

. The RND transporter protein AcrB is responsible for substrate

recognition and energy transduction. Upon binding of a substrate, AcrB uses the energy
from the proton flow down its concentration gradient through a proton translocation

pathway in the transmembrane domain to drive the conformational change necessary to
move the substrate upward toward the exit tunnel

46, 133

. TolC is shared by several efflux

systems, hence E. coli strains deficient in TolC are more sensitive to a wider variety of
chemicals (e. g. detergents, drugs, bile salts, and organic solvents) 50, 51.
With the dedication of many research groups, the structure and mechanism of drug
efflux by the RND pumps have been brought to light. The first crystal structure of the pump
component was determined for TolC by Koronakis et al. 137 in 2000. TolC is a trimer with
an overall length of 140 Å with 40 Å in the β-barrel domain mainly composed of β-strands,
and 100 Å in the periplasmic domain mainly composed of α-helices. The periplasmic end
of the TolC tunnel is sealed at the resting state, which likely opens by an allosteric protein–
protein interaction mechanism

87

. In 2002, Murakami et al. first reported the crystal

structure of AcrB, followed by the proposal of the functional rotation mechanism

64, 65, 78

.

Later in 2006, Mikolosko and coworkers determined the crystal structure of AcrA. In
contrast to the trimeric TolC and AcrB, AcrA forms a hexamer in the pump assembly 138.
The assembled pump structure was first proposed as the “deep interpenetration model”,
which shows that AcrB and TolC have direct interactions with AcrA wrapped around on
the outside to strengthen the interaction

85

. More recently, Wang et al. proposed a new

model based on Cryo-EM studies, known as the “tip-to-tip model”. In this model, AcrA
hairpins form a barrel-like conformation, contacting TolC in a tip-to-tip arrangement 53, 89.
The recent determination of the complex structure first by cryo-EM, then by X-ray
crystallography, confirmed the tip-to-tip model 63, 65, 66, 76, 86-88. Energy does not seem to be
required to assemble the AcrAB-TolC complex and AcrAB could interact with the TolC
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channel to form a AcrAB-TolC complex even in the absence of known substrate

57

. The

dynamic process that leads to the formation of the complex is still elusive.
The dominant negative effect describes the phenomena in which an excess of a
functionless mutant of a protein in the presence of its wild-type counterpart, reduces the
observed activity due to competition from the mutant for interaction with functional
partners of the protein of interest. In the AcrAB-TolC complex, over-expression of
functionless AcrB or AcrA mutant in wild type E. coli strains is expected to drastically
reduce the assembly of functional efflux complex, and thus reduce the efflux activity and
increase the sensitivity to substrate compounds. However, we tested the overexpression of
several functionally defective mutants in the wild type E. coli strain but did not observe the
expected level of reduction. We speculate that the assembly of the AcrAB-TolC is a
precisely controlled process involving delicate proof-reading procedures.

2.2

Materials and Methods
2.2.1

Bacteria strains, plasmids, and growth condition

Escherichia coli BW25113 and BW25113DacrB were obtained from Yale E. coli
genetic resources. BW25113DacrAB, BW25113DacrA were constructed using the E. coli
gene deletion kit (Cat #K006, Gene Bridge) following the manufacturer’s protocol.
Plasmids pBAD33- AcrB and pBAD18-AcrA were created in our previous study

139

,

pBAD33-AcrAB, acrAB gene was amplified from genomic DNA of BW25113 and cloned
into pBAD33 by following the fast-cloning method described previously by Li et al140.
Plasmids pBAD33-AcrB, pBAD33-AcrAB, and pBAD18-AcrA were used as the
templates to create respective mutations discussed below. Mutations were introduced using
the Quikchange site-directed mutagenesis kit following manufacturer’s instructions
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(Agilent, Santa Clara, CA, USA). BW25113spmut, in which the signal peptide of AcrA
was exchanged with the signal peptide of outer membrane protein OmpA, was created
using the CRISPRCas9 system by following the published protocol141. Plasmids pTargetF
and pCas were a gift from Shen Yang (Addgene plasmid #62226 and #62225)141. Bacteria
were cultured at 370C with shaking at 250 rpm in Luria broth (LB) media unless otherwise
noted.
2.2.2

Drug Susceptibility Assay

The minimum inhibitory concentration (MIC) was determined for erythromycin,
novobiocin, ethidium bromide (EtBr), rhodamine 6G (R6G), nalidixic acid (NAL), and
tetraphenylphosphonium chloride (TPP) following the CLSI guidelines142. Briefly,
overnight cultures of the indicated strain were diluted to a final concentration of 105
CFU/mL in fresh Muller Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St.
Louis, MO, USA) in a 48 well microtiter plate containing the indicated compounds at twofold serial dilutions. Plates were incubated at 370C with shaking at 160 rpm for 17 h; the
absorbance at 600 nm (OD600) were measured to identify the lowest concentrations with
no observable cell growth. All experiments were repeated at least three times.

2.2.3

Protein Expression, SDS PAGE and Western blot

For expression test, 5 mL of cells were cultured overnight at 370C with shaking at
250 rpm. The next morning, the cell was inoculated with a 100-fold dilution into a 5 mL
fresh LB media supplemented with antibiotics and grow until ~OD600 1.0. Cells were
pelleted and resuspended in 1 mL phosphate buffer containing phenylmethylsulphonyl
fluoride (PMSF) (1:1000 dilution of a saturated ethanol solution) and sonicated for 1 min
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followed by centrifugation for 10 min at 15,000 rpm. The supernatant was removed, and
cell pellets were resuspended in 0.1 mL PBS containing 2% Triton-X100. The samples
were incubated at room temperature with shaking for 45 min and centrifuged again for 10
min. The supernatant was used for SDS-PAGE and Western blot analysis. For studies of
disulfide bond formation, iodoacetamide (IAM) was added to a final concentration of 20
mM in all buffers. To reduce disulfide bond, β-mercaptoethanol (BME) was added to a
final concentration of 2% followed by incubation at room temperature for 30 min.
For AcrAB dissociation experiment, BW25113 or BW25113ΔacrA containing
plasmid pBAD18-AcrA was cultured to the log phage (OD600 0.8) and arabinose was
added to a final concentration of 0.2% (w/v) to induce the expression of AcrA for 50 min.
The cells were then pelleted, washed, and resuspended with fresh LB. An aliquot of cell
culture was collected, pelleted, and stored at -200C. The rest of the cell culture was returned
to the shaker and cultured for 5 h, and another aliquot of sample was collected, pelleted,
and stored at -200C. The last sample was collected at 17 h. OD600 of the samples were
measured and used to adjust the sample volume collected to ensure that the same number
of cells were used for each time point. All pellets were resuspended and sonicated to lyse
the cells. After centrifugation, the pellet was extracted using PBS + 2% Triton for 2 h. The
mixtures were centrifuged again, and the supernatants were incubated with Ni beads for 40
min, followed by washing with the same buffer supplemented with 50 mM imidazole, and
finally eluted with the same buffer supplemented with 500 mM imidazole. For DSP
crosslinking experiments, the cell pellet was washed and then resuspended in PBS buffer.
DSP was added to a final concentration of 1 mM, and the mixture was incubated at room
temperature for 30 min. To stop the reaction, a Tris-Cl buffer (pH 8.0) was added to a final
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concentration of 20 mM. Cells were then pelleted, and proteins were purified similarly as
described above. To break the disulfide bond in DSP, DTT was added to the sample to a
final concentration of 10 mM.
For Western blot analysis, after transferring to the PVDF membrane, protein bands
were detected using an Anti-AcrB polyclonal (Rabbit) antibody raised to recognize a C
terminal peptide corresponding to residues number 1036–1045143 or Anti-AcrA antibody,
respectively. The membrane was then washed and incubated with an alkaline phosphatase
conjugated goat anti-rabbit secondary antibody. The BCIP/NBT (5-bromo-4-chloro-3’indolyphosphate and nitro-blue tetrazolium) solution was used to stain the membranes. All
experiments were repeated at least three times.

2.3

Results
2.3.1 AcrA Mutants Defective in TolC Interaction
AcrA is the periplasmic adaptor protein of the efflux system. While debate still exists

concerning the conformation of AcrA in the final assembled pump, it was clear that several
residues at the tip of its long α-helical hairpin loop play an important role in the interaction
with TolC 144. We created three such mutants, R128D, L132D, and S139D, and introduced
plasmids encoding these mutants first into BW25113∆acrA to confirm that they are not
active (Table 2.1). As expected, the mutants were largely inactive. The plasmids were then
transformed into BW25113, and substrate susceptibility of the strains were measured. We
did not observe the dominant negative effect.
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Table 2.1 MIC values (µg/mL) of BW25113 and BW25113∆acrA strains containing the
indicated plasmid encoding AcrA mutants.

Substrate1
BW25113∆acrA containing
/
WT
L132D
R128D
S139D
A113D
A155D
A113D, A155D
L50C
I52C
E229C
R225C
L50C, R225C
I52C, R225C
I52C, E229C
BW25113 containing
/
R128D
L132D
S139D
A113D
A155D
A113D, A155D
L50C
I52C
E229C
R225C
L50C, R225C
I52C, R225C
I52C, E229C

NOV

ERY

TPP

R6G

NA

4–8
64
8
4
4
64
8
8
32
32
32
16
4
4
4

2
32
2
2
2
4
4
2
8
4
4
8
8
4
2

4
256
4
4
8–16
32
8
8
32
16
32
64
8
8
4

4
128
4
4
4
16
4
4
32
32
16
16
4
8
4

1
4
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

512
512
512
256
512
512
512
512
256
512
512
512
512
512

64
64
64
64
64
64
64
64
64
64
64
64
128
128

1024
1024
1024
1024
1024
1024
1024
1024
1024
1024
1024
1024
1024
1024

512
512
512
512
512
512
512
512
512
256
512
256
512
512

4
4
4
4
4
4
4
4
4
4
4
4
4
4

1

NOV= Novobiocin, ERY= Erythromycin, TPP= Tetraphenyl phosphonium
chloride, R6G= Rhodamine-6-G, NA= Nalidixic acid, ND = Not determined
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Next, we examined the expression of AcrA from the plasmids. We did not induce
expression. Both the MIC study and the expression level detection experiments were
performed under the basal expression condition. Expressions of the mutants (R128D,
L132D, S139D) were higher than the expression level of the genomic AcrA (Figure 2.1a).
To make the sample intensity comparable on the Western blot analysis, samples prepared
from plasmid-containing strains were diluted 4-fold before being loaded into the gel. Thus,
the expression levels of the mutant AcrA constructs were 10–20 folds higher than the
expression level of the wild type AcrA from the genome. While these mutants had been
studied for their impact on interaction with TolC, it was not clear if they would have an
impact on binding with AcrB. We used the double Cys mutants as described above to probe
the interaction between AcrA-R128D and AcrB (Figure 2.1b). This extra mutation did not
seem to disrupt the interaction between AcrA and AcrB.
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Figure 2.1 Characterization of AcrA mutants defective in TolC interaction. (a) Anti-AcrA
Western blot analysis of samples prepared from BW25113 containing plasmids expressing
the indicated AcrA mutant (diluted 4- folds). Sample prepared from plasmid-free
BW25113 was also prepared and loaded without dilution (\) to serve as a control to
highlight the difference in expression levels. (b) Anti-AcrB and Anti-AcrA Western blot
analyses revealing the formation of disulfide bonded AcrA-AcrB complexes, which was
reduced after incubation with BME. AcrA-P57C/AcrB-N191C, R128D (lane 1 and 3),
AcrA-T217C/AcrB-S258C, R128D (lane 2 and 4). (c) Anti-AcrB and Anti-AcrA Western
blot analyses revealing the formation of disulfide bonded AcrA-AcrB complexes, which
was reduced after incubation with BME. AcrA-P57C/AcrB-N191C (1 and 2), AcrAT217C/AcrB-S258C (3 and 4). Molecular weight markers are labeled as “M” and the
molecular weight of bands (kD) were indicated on the right. The expected bands for AcrA,
AcrB, and disulfide bond linked AcrA-AcrB are marked on the left of the gels as A, B, and
AB, respectively.
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2.3.2 AcrA Mutants Defective in AcrA Assembly
According to the cryo-EM structure of the complex, AcrA forms a hexameric barrel,
with each subunit contributing a long helical hairpin. We speculate that mutations
introduced at neighboring sites between the hairpins would disrupt the interaction between
neighboring AcrA subunits, and thus disrupt the formation of the helical barrel. We chose
two sites to introduce mutation, A113 and A155. They are located at the inter-subunit
interface in the middle of the long hairpin. We created both single and double mutants
containing A113D and A155D. Plasmids encoding these strains were first transformed into
BW25113ΔacrA to examine the impact of the mutation on the efflux activity (Table 2.1).
Both mutations disrupted efflux, as revealed by a reduction of the MIC. The A155D
mutation is more detrimental than A113D. Both A155D and the double mutations
A113D/A155D were largely inactive. When transformed into BW25113, we still did not
observe a significant reduction of MIC. The expression levels of the mutants were
examined to confirm that mutants did express in excess compared to the level of the
genomic AcrA under the experimental condition. As shown in figure 2.2a, the expression
of the mutants was similar or slightly higher than that of the genomic AcrA. We next used
the inter-AcrA/AcrB disulfide bond pairs to examine the impact of A155D mutation on the
interaction between AcrA and AcrB (figure 2.2c). This additional mutation did not have a
significant impact on the level of disulfide bond formation, indicating that it did not disrupt
the interaction between AcrA and AcrB.
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Figure 2.2. Anti-AcrA Western blot analysis of samples prepared from BW25113
containing plasmids expressing the indicated AcrA mutant (diluted 4-folds). Sample
prepared from plasmid-free BW25113 was also prepared and loaded without dilution (/) to
serve as a control to highlight the difference in expression levels. (a) AcrA mutants are
expected to affect AcrA–AcrA interaction during pump assembly. (b) AcrA mutants
forming intra-subunit disulfide bond to be trapped in an inactive conformation. Addition
of BME did not lead to an observable change in mobility. (c) Anti-AcrB and Anti-AcrA
Western blot analyses revealing the formation of disulfide bonded AcrA-AcrB complexes,
which was reduced after incubation with BME. AcrA-P57C/AcrB-N191C, A155DD (lane
1 and 3), AcrA-T217C/AcrB-S258C, A155D (lane 2 and 4).
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2.3.3 AcrA Mutants Defective in Conformational Change
We created three pairs of defective AcrA mutants that are trapped in a
nonfunctional confirmation via a disulfide bond, L50C-R225C, I52C-R225C, and I52CE229C145. Hazel et al. first created these mutants to examine their hypothesis that AcrA
adopts two conformations, a cis-like conformation in which membrane proximal (MP) and
α-helical domains point to the same direction, and a trans-like conformation in which they
point to opposite directions. We created the corresponding single and double mutants and
confirmed that the double mutants were largely inactive when transformed into
BW25113DacrA (Table 2.1), consistent with previous report. Yet, expression of these
mutants in the BW25113 strain did not have a significant impact on the efflux of AcrABTolC substrates. We have also examined the expression of the mutants and confirmed that
they were present in the cells at a higher level than the genomic AcrA (Figure 2.2b)

2.3.4 AcrA Mutants in a Strain Containing Anchor-Free AcrA
Finally, we examined the potential contribution of the lipid anchoring of AcrA on
the stability of AcrA-AcrB interaction. Toward this goal, we engineered a BW25113 strain
(BW25113spmut) in which the signal peptide of AcrA (residue 1–24 encoded in the acrA
gene) in the genome was replaced with the signal peptide of OmpA. The OmpA signal
peptide directs the secretion of the AcrA to the periplasm after synthesis. The lipid
anchoring was abolished, but the activity of AcrA was not affected49. We reason that
removal of the lipid anchoring might favor dissociation of AcrA from AcrB in the AcrAAcrB complex, and thus providing an opportunity for the mutant AcrA, which is lipidanchored, to compete more effectively for binding with AcrB. We transformed above-
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mentioned AcrA mutant into BW25113spmut and measured the MIC of the strains (Table
2.2). We still did not observe a significant reduction in efflux activity.

Table 2.2 MIC values (µg/mL) of BW25113spmut strain containing the indicated plasmid
encoding AcrA mutants
Substrate

NOV

ERY

TPP

R6G

/

512

128

2048

1024

R128D

512

128

2048

1024

L132D

512

128

2048

1024

S139D

512

128

2048

512

A113D

512

128

2048

512

A155D

512

128

2048

512

A113D, A155D

512

128

2048

512

L50C, R225C

512

128

2048

512

I52C, R225C

512

128

2048

1024

I52C, E229C

512

128

2048

1024

2.3.5 Slow Dissociation of the AcrAB Complex
We speculate that the AcrAB complex, once formed, dissociates very slowly. To
experimentally test this speculation, we introduced a plasmid encoding AcrA bearing a
histag at the C-terminus (AcrA-his) into a wild-type and the corresponding acrA knockout
strains. We first confirmed that under our experimental condition, the genomic AcrB could
not be purified using metal affinity chromatography (Figure 2.3a). In the absence of the
plasmid, no AcrB could be detected in the eluate in anti-AcrB Western blot. In contrast,
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when AcrA-his was introduced into the cells, AcrB could be detected in the eluates,
indicating that it was co-purified through interaction with AcrA-his. Interestingly, the AcrB
band intensity was higher in the eluate prepared from the acrA knockout strain, indicating
more AcrB were co-purified. Next, we examined the time course of co-purification. The
rationale is, in the wild-type strain, genomic AcrB and AcrA form stable complexes. If the
dissociation is fast, the introduced AcrA-his will quickly compete with genomic AcrA to
form a complex with AcrB, and in turn enable purification of AcrB through metal affinity
chromatography. Otherwise, if the dissociation is slow, then it takes much longer for the
competition to happen. We monitored the formation of AcrAB complex between the
genomic AcrB and plasmid expressed AcrA-his at three-time points, right after the
induction period, and 5 and 17 h after induction (Figure 2.3b). We performed crosslinking
right before protein extraction and purification to stabilize the complexes. As a control
experiment, we also examined the formation of the AcrAB complex between the genomic
AcrB and plasmid-expressed AcrA-his in an acrA gene knock-out strain. In this case, we
do not expect competition from the genomic AcrA; thus, complex should form faster. We
found that the formation of the complex is plateaued much faster in the acrA knockout
strain, as intensities of the eluates prepared from 5 and 17 h into incubation were very
similar. In contrast, it took much longer for AcrB to interact with AcrA-his in the wildtype strain, which is likely due to the requirement of an extra step of AcrAB dissociation
between the genomic AcrA and AcrB.
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Figure 2.3 Co-purification of genomic AcrB with AcrA-his. (a) Anti-AcrB Western blot
analyses of samples prepared from BW25113 or BW25113ΔacrA with or without plasmidencoded AcrA-his. (b) Anti-AcrB Western blot analyses of samples collected after 0, 5, or
17 h of incubation following the induction of AcrA-his production in BW25113 or
BW25113ΔacrA strains. Dithiobis- (succinimidyl proprionate) (DSP) crosslinking was
performed to stabilize the AcrAB complex before protein purification. Reduction using
dithiothreitol (DTT) breaks the disulfide bond in the linker of DSP and the complex into
AcrA and AcrB subunits. Molecular weight markers are labeled as “M”, and the molecular
weight of bands (kD) were indicated on the right. The expected bands for AcrB and DSP
linked AcrA-AcrB are marked on the left of the gels as B and AB, respectively.
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Figure 2.4 Structure of the AcrAB-TolC complex with the residues mutated in this study
highlighted in AcrA structure. AcrA mutations labeled as; A1-L50C, A2-I52C, A3-P57C,
A4-A113D, A5-L132D, A6-S139D, A7-A155D, A8-T217C, A9-R225C, A10-E229C.
Structure is created using pymol from 5N5G.pdb (https://pymol.org/2/)(accessed on 15
March 2021).

2.4

Discussion
The dominant negative effect describes the situation in which the phenotype is

dominated by the negative impact of the functionless mutant. The observation of the
dominant negative effect has been used in many studies to investigate the mechanism of

39

protein– protein interaction, including the identification of protein–protein interactions
interface

146

, determination of enzymatic activity related to oligomerization147, and the

effect of mutations in genetic disorders 148, 149.
In the process of AcrAB-TolC assembly, there are many steps where the
incorporation of a functionless AcrA or AcrB mutant would negatively impact the efflux
activity. First, all three proteins in the system are oligomers. AcrB and TolC are obligate
timers, while AcrA is believed to exist as a dimer or trimer in the free form and assembles
into a hexamer in the pump complex 49, 150. While AcrA and AcrB are believed to form a
complex in the absence of substrate and efflux, TolC assembles with AcrAB during active
efflux. When a functionless AcrA mutant is expressed in excess in a wild type E. coli cell
containing genomic AcrA, we expect them to compete with their genomic counterpart to
engage genomic AcrB, forming non-functional interactions to reduce the overall efflux
activity. In addition, we expect the competition for genomic TolC will further enhance the
dominant negative effect. For this competition to occur, we chose mutants that are defective
due to mechanisms not directly related to the interaction between AcrA and AcrB. The
structure of the AcrAB-TolC complex and location of mutants mentioned in this study are
shown in Figure 2.4. We determined the expression level of the mutants relative to their
genomic counterpart. Using serial dilution and quantitative Western blot analysis, we found
that the expression levels of the AcrA mutants were 2 to 20 folds of the level of the genomic
AcrA. With this excess, we expect to observe strong dominant-negative effect if the
mutants were actively involved in the pump assembly, competing for binding partners. We
constructed three groups of AcrA mutants, defective in different aspects.
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The first group of residues we tested are ones that impact AcrA interaction with
TolC, as they are involved in the tip-to-tip interaction with TolC 144. We confirmed that a
representative mutant in this group, R128D, still binds to AcrB (Figure 2.2b). Similarly,
we expect the expression of these mutants will lead to competition with genomic AcrA for
genomic AcrB, and the formation of a nonfunctional complex. However, no reduction of
MIC was observed. To further probe the interaction of AcrA and AcrB, we created a strain
of E. coli that is genetically modified to replace the signal peptide of AcrA with the signal
peptide of OmpA (BW25113spmut). The resultant AcrA can still be secreted into the
periplasm and is fully functional, but the lipid anchoring is lacking

49

. With this free-

floating AcrA, we expect the interaction between AcrA and AcrB to be weakened, which
may increase the competitiveness of the plasmid encoded AcrA, which is lipid anchored.
Yet, we did not observe a reduction of MIC when the functionless mutants were expressed
in strain BW25113spmut.
The next group of AcrA mutants contains changes at the inter-subunit interface of
AcrA to disrupt formation of the functional hexametric ring. While the A155D single
mutation was enough to completely abolish activity, expression of the protein in BW25113
did not lead to a reduction of MIC. Finally, we examine a group of AcrA that forms
disulfide bond locked conformation that is functionally incompatible. Again, similar as
other groups, over-expression of these mutants did not have a significant impact on MIC.
In conclusion, we examined the effect of plasmid-encoded AcrA in wild type E.
coli cells, to probe the potential disruption of normal AcrA-AcrB-TolC assembly in the
presence of excess mutants of AcrA or AcrB. To our surprise, none of the three groups of
mutants showed the so-called “dominant negative” effect. This observation indicates that
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the RND pump assembly process in Gram-negative bacteria is a precisely controlled
process that prevents the formation of functionless complex. An alternate explanation is
the possibility that efflux depends on only a very small population of AcrAB-TolC pumps
active at a given moment, as the population of active AcrAB-TolC pumps was not
detectable in situ in E. coli 87. If the majority of AcrAB and TolC in the cells are idle, then
the effect of over-expressing functionless mutant would be greatly limited. In addition, our
results suggest that dissociation kinetics of the AcrAB complex is very slow. Once formed,
the complex remains bound and does not dissociate easily.
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CHAPTER 3. FUNCTIONAL RELEVANCE OF ACRA: ROLE OF THE
UNSTRUCTURED REGIONS AND ACRA-ACRA FUSION IN ACRAB-TOLC
EFFLUX SYSTEM IN E. COLI

3.1

Introduction
AcrA is a member of periplasmic adaptor proteins (PAPs) which were originally

known as the membrane fusion proteins, due to their perceived sequence similarity to the
paramyxoviral SV5 fusion protein 151. It belongs to the tripartite efflux pump bridging the
transporter protein AcrB, and the outer membrane channel, TolC 80, 136. Together with low
permeability of the bacteria membrane, these components contribute to drug resistance by
working in concert for the efflux of a broad range of compounds out of the bacteria system.
12, 72

. Localized in the periplasmic space, AcrA is anchored to the outer leaflet of the inner

membrane at its N-terminal end by its lipidated cysteine residue 152. With other PAPs, it is
comprised of α helical hairpin, lipoyl, ẞ-barrel and membrane proximal domains

49, 82, 83

.

Studies have shown that α helical hairpin domain interacts with TolC while the other
domains interact with AcrB

153, 154

. In crystal structures though, some residues at the N-

terminal (NT) end (26-37) and the C-terminal (CT) domains of AcrA are not resolved, and
their structures remain unknown, thus indicating a degree of conformational flexibility of
the protein 138, 155.
This study explores the functional relevance of the unresolved NT and CT of AcrA
and the potential impact of AcrA-AcrA fusion protein in efflux mediated by AcrAB-TolC
pump. To probe potential role of the NT peptide other than membrane anchoring, we
investigated the effect of length. If the peptide adopts an alpha helical conformation, then

the number of residues required to extend from the membrane anchor into the periplasm
should be about eight, as the alpha helix has the rise per residue of 1.5Å. On the other hand,
since beta sheet has the rise per residue of 3.5 Å, if the unstructured N-terminal region of
AcrA is a beta sheet, then the number of residues needed for the protein to rise to the
periplasm should be about three. In any case, 12 unresolved residues may not be necessary
for either of the two secondary structural conformations. At the CT, we truncated the
protein synthesis by introducing stop codons to replace amino acid residues at several
positions of the peptide. Drug susceptibility and expression of the mutants were
determined.
For the tripartite AcrB-AcrA-TolC complex, both 3:3:3 and 3:6:3 models have been
postulated156. In vivo chemical cross-linking experiments between AcrA-AcrB & AcrA TolC complex shows 1:1:1 stoichiometry. However, surface plasmon resonance
experiments showed that AcrA exists as a dimer

48, 152

and that the dimer is the unit that

binds to TolC, hinting at a 1:2:1 stoichiometry in vitro. Cryo-electron microscopy (cryoEM) imaging recently reveals a 3:6:3 model of the AcrB-AcrA-TolC assembly136,

157

,

precluding any interactions between AcrB and TolC. This conflicts with the results of
previous in vivo direct disulfide cross-linking experiments. In this study we created AcrAAcrAΔ25 fusion proteins with a flexible linker. This is the first time to our knowledge that
these fusion constructs have ever been created. The signal peptide sequence and cysteine
25 of the second AcrA unit were removed, and a flexible 3(GS) linker was created to aid
the dimerization of the long mutant. The rationale was to probe which of the stoichiometric
ratios reflects the functional state within the cell. The fusion proteins showed expression
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levels comparable to the wildtype AcrA and was efflux efficient in AcrA-deficient cells.
Then we introduced inactive mutants like R128D, A155D on the fusion construct.

3.2

Materials and Methods
3.2.1

Bacteria Strains, Plasmids, and growth conditions

E. coli DH5α cells were used throughout the experiments as host for cloning. The AcrA
mutations were created using the E. coli RAM1418∆AcrA in which the genomic acrA gene
was replaced with kanamycin gene 158. Thus, RAM1418∆AcrA cells without plasmids was
cultured at 37oC in LB media supplemented with kanamycin (50 µg/ml) while cells that
harbors the mutants in pBAD18 AcrA plasmids were grown in LB media supplemented
with ampicillin (100 µg/ml).
3.2.2

Construction of Mutants

Site directed mutagenesis was performed to introduce the stop codons at the C terminus of
AcrA using the Quick-change protocol (Agilent technologies). The N terminal deletions
were performed using the fast cloning protocol

140

. To create the fusion proteins, we

designed both forward and reverse primers to contain Xho1 sites, while the forward primer
contained the linker sequence. We then used PCR to amplify the AcrA Δ1-25 between the
Xho1 sites in pBAD18AcrA. All mutations were confirmed by sequencing. The primers
used for the mutations are listed in Table 3.

3.2.3

Protein expression, SDS-PAGE, and Western Blot

For expression test, 5 mL of cells were cultured overnight at 37 °C with shaking at
250 rpm. The next morning, the cell was inoculated 100-fold into a 5 mL fresh LB media
supplemented with antibiotics and allowed to grow until ~OD600 1.0. Cells were pelleted
and resuspended in 1 mL phosphate buffer containing phenylmethylsulphonyl fluoride
(PMSF) (1:1000 dilution of a saturated ethanol solution) and sonicated for 1 min before
centrifugation for 10 min at 15,000 rpm. The cell pellets were resuspended in 0.1 mL PBS
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containing 1% Triton-X100. The samples were incubated at room temperature with
shaking for 30 min and centrifuged again for 10 min. The supernatant was used for SDSPAGE and Western blot analysis.
For Western blot analysis, after transferring the SDS gel to the PVDF membrane,
protein bands were detected using an Anti-AcrA antibody polyclonal (Rabbit) antibody
raised to recognize AcrA. The membrane was then washed and incubated with an alkaline
phosphatase conjugated goat anti-rabbit secondary antibody. The BCIP/NBT (5-bromo-4chloro-3’-indolyphosphate and nitro-blue tetrazolium) solution was used to stain the
membranes. All experiments were repeated at least three times.

3.2.4

Drug Susceptibility Assay

The minimum inhibitory concentration (MIC) was determined for chloramphenicol
(CHL), erythromycin (ERY), nalidixic acid (NAL), novobiocin (NOV), rhodamine-6G
(R6G), tetracycline (TET) and tetraphenylphosphonium chloride (TPP) following the
guidelines of Clinical and Laboratory Standard institute (CLSI)142. Briefly, overnight
cultures of the indicated strain were diluted to a final concentration of 105 CFU/mL in fresh
Muller-Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St. Louis, MO). This was
done in a 48 well microtiter plate containing the indicated compounds at two-fold serial
dilutions. Plates were incubated at 370C with shaking at 160 rpm for 17 hours. The
absorbance at 600 nm (OD600) was measured to identify the lowest concentrations with
no observable cell growth. All experiments were repeated at least three times.
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3.3

Result
3.3.1

Role of the NT Residues

The AcrA protein is a three hundred and ninety-seven (397) amino acid residues
long protein. The first twenty-four (24) residues are the SP responsible for the translocation
of the protein across the inner membrane into the periplasm with NT cysteine 25 as the
membrane anchor 159, 160. Residues 26-37 at the N -terminal end were not resolved in the
AcrA structure 161.

Table 3.1 Drug susceptibilities of AcrA N-terminal Mutants
Mutant
RAM1418∆A
pBAD18AcrA
pBAD18AcrA
∆Q31QGG34
pBAD18AcrA C25S
pBAD18AcrA
∆Q31QGG34, C25S
pBAD18∆AcrASP
OmpASP
pBAD18∆AcrASP
OmpASP∆Q31QGG34
pBAD18OmpASP
∆AcrASP∆ 26-31
pBAD18OmpASP
∆AcrASP∆ 26-34
pBAD18OmpASP
∆AcrASP∆ 26-36
pBAD18OmpASP
∆AcrASP∆ 26-36
M37S
pBAD18OmpASP
∆AcrASP∆ 26-37

MIC (µg/ml)
NAL
NOV
1
8
4
128
1
8

CHL
0.5
2
1

ERY
4
64
8

R6G
16
256
16

TET
0.25
1
0.5

TPP
16
256
16

2
1

64
8

4
2

128
16

256
32

0.5
1

256
32

4

128

4

256

512

2

512

4

64

4

256

512

1

512

4

128

4

256

512

1

512

4

64

4

128

512

1

512

4

64

4

128

256

1

256

4

64

4

256

512

2

512

1

8

1

32

32

0.5

16
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AcrA is anchored through Cys25 on the outer leaflet of the inner membrane. If the
role of the NT residues 26-37 is merely to span the space between the membrane surface
and the function modules of AcrA, then the short sequence should be replaceable by any
residues, and truncation of the residues should lead to the shortening of the “rope” and
disruption of AcrA function. Upon removal of the anchor, we should restore activity.
We first checked the importance of length. To make the anchor shorter, we deleted
four residues, Q31QGG34 resulting in loss of activity against the tested substrates. We
implied that the peptide played additional roles other than membrane anchoring, as even
the length of eight (8) residues left after Q31QGG34 deletion should be enough to span the
distance between the membrane surface and proline 38. Next, we mutated C25 into Ser,
which precludes its lipidation and membrane anchorage. Earlier studies showed that
mutation of C25 resulted in the disruption of the cleavage of the signal peptide with the
protein accumulating on the cytoplasmic side of the membrane

159

. Thus, the uncleaved

signal peptide folded as a transmembrane helix with AcrA retaining its activity. (Table 1).
We speculate that the transmembrane helix formed by the SP has a certain degree of
flexibility in vertical movement in the cell membrane, or it might extend out from the outer
leaflet of the inner membrane that the functional AcrA domain could rise high enough to
interact with AcrB.
In an earlier study, the SP of AcrA was replaced with that from outer membrane
protein A (OmpA)

49

. The OmpA SP was effective in directing the export of AcrA to the

periplasm. Although no longer anchored to the membrane surface, AcrA with the new SP
was fully active. If in the Q31QGG34 mutant, the loss of activity is due to the shortening of
the anchor, then we expect that removal of the anchor would restore activity. We then
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introduced the Q31QGG34 deletion into the OmpA-AcrA construct (∆AcrASP
OmpASP∆Q31QGG34). As shown in Table 3.1 the construct is fully active, consistent with
our speculation.
Next, we speculated that in the case of ∆AcrASP-OmpASP, since AcrA is no longer
tethered to the membrane surface, the deletion of the NT residues might be tolerated. We
created additional mutations in which different segments of the NT peptides were removed.
We found that at least part of the sequence is still needed, with the removal of residues 2637 resulting in a significant loss of AcrA activity.

Figure 3.1 (a). Expression levels of AcrA NT mutants using membrane fractions. ∆AcrA
(1), wild- type (2), AcrA C25S (3), ∆Q31QGG34 (4), AcrA ∆Q31QGG34C25S (5), Marker
(6) (b.) Expression levels of AcrA-OmpASP NT mutants using periplasmic fractions.
∆AcrASP-OmpASP (2), ∆AcrASP-OmpASP ∆Q31QGG34 (3), ∆AcrASP-OmpASP∆26-31
(4), OmpASP-∆AcrASP∆ 26-34 (5), OmpASP ∆AcrASP∆ 26-36 (6), OmpASP ∆AcrASP
∆26-37 (7) (c) Comparison of expression with genomic AcrA: OmpASP ∆AcrASP∆ 2636 (2), OmpASP ∆AcrASP ∆26-37 (3) and AcrA from E. coli MG1655 wildtype strain (4)
(d) Expression test of OmpASP ∆AcrASP∆ 26-36 M37S (2)
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3.3.2

The C-terminal Unresolved sequences are required for AcrA function

While the structure of AcrA fragments have been determined in several studies, the
full length AcrA turned out to be difficult to crystalize

85, 138

. In a recent study using

cryo-electron microscopy, the structure of the entire E. coli AcrABZ-TolC was reported
53

. The AcrA structure in this complex is the most complete compared to other models.

In this structure, all major AcrA domains, ranging from residue P38 to E377, were
resolved. The C-terminus of AcrA has been shown to be important for function of the
efflux pump

152

. To determine the potential role of the unresolved sequence, we

constructed a series of truncation mutations in which the C-terminal residues of AcrA
was systematically removed. The resultant truncation mutants were transformed into
the AcrA knockout strain RAM1418∆AcrA to evaluate the impact on function. As
shown in Table 1, truncation of translation from E377 to 397 has no detectable impact
on the efflux of selected substrate. The removal of one additional residue, Q376,
drastically compromised activity, and further removal of K374 and A375 eliminated
AcrA activity.
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Table 3.2 Drug Susceptibilities of AcrA C-terminal Mutants
Mutant
RAM1418∆A
pBAD18AcrA
pBAD18AcrA
A380stop
pBAD18AcrA
V378stop
pBAD18AcrA
E377stop
pBAD18AcrA
Q376stop
pBAD18AcrA
A375stop

MIC (µg/ml)
NAL
NOV
R6G
1
8
16
4
128
256
4
128
256

CHL
0.5
2
2

ERY
4
64
64

TET
0.25
1
1

TPP
16
256
256

2

64

4

128

256

1

256

2

64

4

128

256

1

256

1

16

2

16

32

1

32

1

16

2

16

32

1

32

To determine if the reduction of activity is due to reduced expression, we compared
the expression level of all mutants. As shown in Figure 1A, the expression level of all
proteins is similar except for A375 and K374. Thus, the reduced efflux is not due to poor
expression except for K374 and A375 mutations with no expression. This result indicates
that the 20-residue flexible C-terminal tail is dispensable and not important for activity, but
residues before Q376 are critical for AcrA activity.
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Figure 3.2 Expression level of the C-terminal mutants. ∆AcrA (1), wild type (2), Marker
(3), A380stop (4), V378stop (5), E377stop (6), Q376stop (7), A375stop (8), K374 (9).

Figure 3.3 AcrA with cartoon representation of the mutated residues at the N and C
terminals
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3.3.3

Interaction of defective AcrA mutant at the N and C terminals with AcrB—
competition assay
To probe the interaction of the inactive AcrA mutants with AcrB, we adopted a

competition assay. The rationale is that the mutant AcrA from plasmid will compete with
the genomic AcrA for binding to AcrB, which is usually at a much lower expression level
than the mutant AcrA. So, we transformed the plasmid encoding the inactive
AcrAK374stop and AcrA ∆Q31QGG34 mutants into the WT strain. We also co-transformed
the mutants with a pBAD33 AcrB (pB) and examined if over expression of the mutants has
a negative impact on efflux. This phenomenon is called the dominant negative effect. It
describes the condition in which the phenotype is dominated by the negative effect of a
functionless mutant131. The observation of the dominant negative effect has been utilized
to examine the mechanism of protein–protein interaction146 and the impact of mutations in
genetic abnormalities149, 162.
If the mutant AcrA has similar affinity to AcrB as the genomic wild type AcrA, the
majority of AcrB would be occupied by the mutant AcrA, which is not functional, and thus
the overall efflux would be lower. We observed no dominant negative effect. This result
aligned with that of our previous study which concluded the RND pump assembly process
in Gram-negative bacteria is a precisely controlled process that prevents the formation of
functionless complex131.
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Table 3.3 Drug Susceptibilities for Competitive Binding of AcrA Constructs with AcrB
Mutants
BW25113∆acrA
BWWT
pBAD18 AcrA+ BW25113WT
pBAD18 AcrA +
BW25113∆AcrB+ pB
pBAD18 ∆AcrA∆Q31QGG34+
BW25113WT
pBAD18AcrA∆Q31QGG34+pB+
BW25113∆AcrB
pBAD18 AcrA K374 Stop +
BW25113WT
pBAD18 AcrA K374Stop + pB
+BW25113∆AcrB

3.3.4

MIC (µg/ml)
ERY
TPP
2
4
128
1024
256
1024
256
512

R6G
4
1024
1024
1024

256

128

512

512

256

128

512

1024

256

128

512

1024

512

128

512

1024

NOV
4-8
512
512
512

AcrA-AcrA Fusion
Previously it was shown by Hayashi et al that AcrB-AcrA fusion proteins in a 1: 1

ratio was efflux efficient47. They used different linkers as transmembrane connection to
link the C terminus of AcrB with AcrA N terminus. The acrB-or acrAB-deficient strains
harboring plasmids encoding AcrB-AcrA fusion showed MIC values like the wild-type
AcrB-or AcrAB -expressing strains. They suggested that fusion proteins function in place
of AcrB or a combination of independent AcrB and AcrA proteins. They reported that their
findings support the 1: 1: 1 ratio and not the 1:2:1 ratio implying that there are 3 AcrAs
around each trimeric AcrB. They argued that to make AcrB-AcrA fusion construct in a 1:2
ratio it will require the borrowing of AcrA from neighboring AcrB-AcrA fusion because
of steric hinderance due to the proximity of AcrB, as fusion protein without a linker showed
efflux efficiency too.
Based on this finding, we created AcrA dimers made up of a long piece of two
AcrAs with a flexible linker (AcrA-3(GS)-AcrA Δ1-25. The mutants created were
expressed in AcrA -deficient RAM1418 ΔacrA cell and tested the efflux activity against
substrates. We reasoned that a functional construct implies that the dimer retains its ability
to interact and function with AcrB trimer.
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We then proceeded to create the same AcrA dimer AcrA R128D-3(GS)-AcrA Δ125, with the first full length AcrA mutated to a non-functional R128D

144

. Our result

showed that the mutant was efflux efficient. Again, we created a construct with a nonfunctional AcrA A155D mutation 131 , one in the full-length pair and the other in the second
truncated pair (AcrA A155D-AcrA Δ1-25 and AcrA-AcrA A155D Δ1-25). The
expectation is that if the construct is fully active, it probably points to a functional 1:1:1
AcrB-AcrA-TolC ratio as the inactive pair should not interfere with function. However,
inactive constructs will support the 1:2:1 ratio, with the implication that both AcrA unit
will have to be functional to maintain interaction with AcrB and TolC. We did the
expression tests & MIC and found that the constructs were also efflux active in AcrA
deficient cell. However, while the result leans towards supporting the 1:1:1 ratio, this
conclusion cannot be reached definitely because of the non-specific cleavage to monomers.
Assembly of monomers may have contributed to the observed activity thus eliminating the
possibility that the observed effect is solely a result of the dimeric construct.

Figure 3.4 Expression Test for AcrA Fusion mutants. Marker (1), Genomic AcrA (2), AcrA
WT (3), AcrA- AcrA Δ25 (4), AcrA R128D - AcrA Δ25 (5), AcrA A155D- AcrA Δ25(6),
AcrA A155D- AcrA Δ25 (7), AcrA A155D- AcrA A155D Δ25 (8)
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Table 3.4 Drug Susceptibilities of AcrA-AcrA Fusion Mutants
Mutant
RAM1418ΔacrA
No plasmid
pBAD18AcrA
pBAD18AcrAAcrAΔ1-25
pBAD18AcrA
R128DAcrAΔ1-25
pBAD18AcrAAcrA A155D
Δ1-25
pBAD18AcrA
A155DAcrAΔ1-25

MIC (µg/ml)
NAL
NOV
R6G
1
8
16
4
128
256
4
128
256

CHL
0.5
2
2

ERY
4
64
64

2

64

4

128

2

64

4

2

32

2
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TET
0.25
1
1

TPP
16
256
256

256

1

256

128

256

1

256

128

256

1

256

Table 3.5 Primers used in this study
Construct

Primer (5’-3’)

AcrA A380stop-F

GCACAAGAAGTTACCTAAGATAATAACCAGCAAGCCGCAAGC
GG
CCGCTTGCGGCTTGCTGGTTATTATCTTAGGTAACTTCTTGTG
C

AcrA A380stop-R

AcrA V378stop-F

CTGGTTATTATCAGCGGTTTATTCTTGTGCTTTTACCTGGACAC
CAGG

AcrA V378stop-R

CTGGTTATTATCAGCGGTTTATTCTTGTGCTTTTACCTGGACAC
CAGG

AcrA E377stop-F

CGTCCTGGTGTCCAGGTAAAAGCACAATAAGTTACCGC

AcrA E377stop-R

GCGGTAACTTATTGTGCTTTTACCTGGACACCAGGACG

AcrA Q376stop-F

GTCCAGGTAAAAGCATAAGAAGTTACCGCT

AcrA Q376stop-R

AGCGGTAACTTCTTATGCTTTTACCTGAC

AcrA A375stop-F

CGTCCTGGTGTCAGGTAAAATAACAAGAAGTTACCGC

AcrA A375stop-R

GCGGTAACTTCTTGTTATTTTACCTGGACACCAGGACG

AcrA K374stop-F

CGTCCTGGTGTCCAGGTATAAGCACAAGAAGTTACCGC

AcrA K374stop-R

GCGGTAACTTCTTGTGCTTATACCTGGACACCAGGACG

AcrA C25S-F

CAGCTTAGCCCTAACAGGATCTGACGACAAACAGGCCC

AcrA C25S-R

GGGCCTGTTTGTCGTCAGATCCTGTTAGGGCTAAGCTG

AcrA ∆Q31QGG34-F

CAGGCCCAGCAGATGCCCGCCGTTG

AcrA ∆Q31QGG34-R

GGATGTGACGACAAACAGGCC CAGCAGATG
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Table 3.5 (continued)
OmpASP ∆AcrASP∆ 26-31-F

GCTACCGTAGCGCAGGCCCAAGGTGGCCAGCAGATGCCC

OmpASP ∆AcrASP∆ 26-31-R

CGCTACGGTAGCGAAACCAGC

OmpASP ∆AcrASP∆ 26-34-F

GCTACCGTAGCGCAGGCCCAGCAGATG

OmpASP ∆AcrASP∆ 26-34-R

CGCTACGGTAGCGAAACCAGC

OmpASP ∆AcrASP∆ 26-36-F

GTAGCGCAGGCCATGCCCGCC

OmpASP ∆AcrASP∆ 26-36-R

CGCTACGGTAGCGAAACCAGC

OmpASP ∆AcrASP∆ 26-37-F

GCTACCGTAGCGCAGGCCCCCGCCGTTGGCGTAGTAACAG

OmpASP ∆AcrASP∆ 26-37-R

CCTGCGCTACGGTAGCGAAACC

AcrA-Xho1-F

GAACCGCTCGAGGTTCTGGTTCTGGTTCTGGACGACAAACAG
GCC
CGGTTCCTCGAGTCAAGACTTGGACTGTTCAGGCTG

AcrA-Xho1-R

3.4

Discussion
The AcrA protein is a three hundred and ninety-seven (397) amino acid residues long

protein. The first twenty-four (24) residues is the signal peptide responsible for the
translocation of the protein across the inner membrane into the periplasm of the E. coli 159
with NT cysteine 25 as the membrane anchor 160.
In examining the structure of the protein, certain residues are not stable, cannot be
crystallized and hence disordered in the crystallographic structure of the entire protein
sequence. This includes the residues 26-37 at the N -terminal end and the last twenty (20)
amino acid residues at the C-terminal end

161

. Since the structure of these residues is not

defined, the role they play as it relates to the overall function of AcrA cannot yet be
concluded. To explore these unstructured regions, we created truncation mutations at the
N and C terminal regions of the protein, then we checked for the activity against substrates
and performed an expression test of the protein.
At the N terminus, QQGG residues at positions 31-34 were deleted (∆Q31QGG34).
This deletion mutant did not show any activity towards the substrates. We implied that the
function of these residues may extend beyond merely linking the unstructured residues to
proline 38. The length of eight (8) residues left after ∆Q31QGG34 should be adequate to
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extend the distance between the membrane surface and proline 38. We also hypothesize
that the shortened length of the protein prevented its entry into the periplasm, hence the
inactivity. We replaced the first twenty-five (25) amino acids of AcrA (cysteine less AcrA)
with the signal peptide of outer membrane protein A (OmpA) and activity was restored.
We speculate that just like previous studies, the signal peptide of OmpA was at least
partially cleaved by signal peptidase

155

, allowing the free flow of the protein in the

periplasm thereby restoring its activity. AcrA became inactive upon deletion of residues
26-37 (OmpASP ∆AcrASP∆26-37) even though enough of the mutant compared with the
chromosomal AcrA was still expressed. This suggests that methionine at position 37 might
be key to the protein function. Mutation of the non-conserved methionine at position 37
with serine, a short side-chain polar amino acid in the OmpASP ∆AcrASP∆ 26-37 mutant
did not affect the protein expression and the constructs was active against the tested
substrates. This shows that having a residue at position 37 is important but the identity of
the residue might not be important.
At the C-terminal end of the protein, we introduced the stop codon to replace the
residues at different positions such that protein synthesis is disrupted. The goal is to get to
a residue that will be so important in its structure that its deletion will preclude the activity
of the protein. The protein mutants were expressed until residues 374 and 375 that showed
no expression. Thus, suggesting full degradation of the unexpressed protein mutants by
protease. All mutations created did not affect the activity of the protein until position 376
(Q376 Stop) where the activity of the protein was decreased severely. Then mutation at
positions 374 (K374 Stop) the protein became fully inactive. This could be because lysine
(K) residue at position 374 is conserved amongst AcrA and its homologs, which means
that it could be very important in the activity of the protein and hence indispensable. We
also established that plasmid encode AcrA ∆Q31QGG34 and AcrA K374stop, two inactive
AcrA mutants did not exhibit the dominant negative effect. Our reasoning is that the
overexpression of these mutants in a plasmid should improve their chance of outcompeting
the lesser expressed genomic AcrA for binding to genomic AcrB. We also tested this effect
in an AcrB deficient cell complemented with a plasmid encoding AcrB, but there was still
no reduction in MIC. This observation tallies with our previous findings that the assembly
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of the RND pump in Gram-negative bacteria is a strictly regulated event that prevents the
formation of futile complex131
In a bid to further probe the functionally relevant stoichiometry of the AcrAB-TolC
efflux system in E. coli, we created several AcrA fusion proteins in a 1:1 ratio. These
mutants contained one unit of wildtype AcrA, a second unit with the signal peptide and the
cysteine residue at position twenty-five removed and a flexible linker linking both units.
Removal of the signal peptide of the second unit was to enable the dimerization of the
protein and interaction with AcrB. We introduced non-functional mutations R128D and
A155D into these dimeric mutants to probe the effects on drug efflux. The expression of
the AcrA dimers was at a comparable level and showed similar activities as the wildtype
AcrA. This led us to conclude that the previously postulated 1:1:1 stoichiometry of the
AcrB-AcrA-TolC is functionally relevant even though it is conflicted by a more recent
1:2:1 ratio of assembly suggested by cryo-EM.
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CHAPTER 4. PROBING THE FUNCTIONAL RELEVANCE OF THE TIP-TOTIP

4.1

ACRAB-TOLC STRUCTURAL MODEL

Introduction
Drug resistance is largely recognized as a major problem in the treatment of

infectious diseases 12, 163. Efflux pumps and low permeability of the outer membrane of the
gram-negative bacteria are major culprits in multi drug resistance

13, 35

. One of the most

studied efflux systems is the AcrAB-TolC, that comprises of a periplasmic adaptor AcrA,
an inner membrane resistance nodulation cell division (RND) transporter AcrB, and an
outer membrane channel TolC 150, 164.
Together AcrAB-TolC spans the entire bacteria cell envelope to export drug and a
wide variety of other substrates thus reducing the concentration of substrates inside the
bacteria

80, 136

. While the structure of the entire AcrAB-TolC complex has been recently

determined by EM

53

, the dynamic process including for the formation of the delicate

molecular machinery and the concerted conformational changes during efflux remains
elusive 48, 165, 166. AcrB and TolC exist as obligate trimers 57, 136, but the structure of AcrA
during the assembly process is not well defined. Because it bridges the inner and outer
membrane component, AcrA is expected to be more flexible and may undergo large scale
conformational changes during the complex assembly 139, 145.
Two models have been postulated to explain the assembly of efflux pumps: the deep
interpenetration model and the tip-to-tip model 65, 82. Until a couple of years ago, the ‘deep
interpenetration model’ is considered mainstream. According to the model, the docking
domain of AcrB directly interface with the bottom of TolC, with AcrA wrapped around on

the outside to strengthen the interaction. Individual hairpins of AcrA docks into discrete
grooves on the TolC surface 85, to form helical bundle between hairpin of AcrA and TolC
coiled coil. The ‘tip to tip model’ originated from cryo-EM structural studies

136

, the

hairpin domain of AcrA forms a barrel and contacts TolC in a tip-to-tip fashion. No direct
interaction between AcrB and TolC could be observed in this model. Though the final
structure of AcrA in the complex is a hexamer forming a barrel structure 52, it is not clear
at which point AcrA assembles into this format. While the first model is supported by a
plethora of experimental data including but not limited to surface plasmon resonance,
isothermal calorimetric studies and crosslinking conducted in cells, the tip to tip model as
stated earlier is derived from cryo-EM studies of the assembled AcrAB-TolC

51, 53, 130

.

More recently, the in-situ structure of the pumps complex over-expressed in E. coli has
been determined using cryo-ET

87

. The major difference between the two models is the

structure and conformation of AcrA in the periplasm. Since both models are supported by
solid experimental data, there is a possibility that both are snapshots of the complex at
different time point of its assembly and function cycles.
In this work, we used disulfide trapping to probe the structure and conformation of
AcrA oligomers in E. coli cells, and the binding interaction of AcrA and AcrB. The sites
of mutation and introduction of disulfide bond were chosen based on the tip-to-tip model
from the cryo-EM AcrABZ-TolC complex structure

53

. The Disulfide by Design 2.0

(DbD2), a web-based software was used to detect candidate sites for the introduction of
disulfide bond, based on the 5ng5 pdb structure 167. To probe the in vivo AcrA oligomeric
state, we engineered sites at the inter-subunit interface between neighboring AcrA
protomers in the hexamer. We used these sites as probes to examine factors that affects the
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hexameric structure of AcrA if the presence of AcrB or TolC affects oligomer formation.
Next, we engineered disulfide bonds at four spots on the AcrA-AcrB interface: at the AcrA
beta-barrel domain - AcrB DN subdomain (AcrA R59C-G257C and AcrA P57C- AcrB
N191C), and AcrA lipoyl domain - AcrB DN subdomain (AcrA Q269C-AcrB Q197C and
AcrAT217C-AcrB S258C). Our goal is to examine if disulfide could form at these sites,
and if so, would the crosslink affect efflux activity.

4.2

Materials and Methods

4.2.1 Strains and Plasmid
E. coli DH5α was used frequently as host for cloning methods. Knock out strains
RAM1418∆acrA, MG1655∆acrAB and MG1655∆acrABtolC with arabinose inducible
plasmids pBAD18acrA and pBAD33acrAB were used throughout the experiment for over
expression of AcrA and AcrB. The knockout strain was commercially purchased. Growth
of bacteria was done on LB broth and LB agar media at 37◦C.

4.2.2

Cloning and Mutagenesis

Based on the tip-to-tip model of the efflux pump system, we created disulfide bonds
by using quick change site directed mutation to introduce several double cysteine
mutations. With plasmids pBAD18acrAhis we introduced disulfides at the inter-subunit
interface

between

helix

hairpins

of

neighboring

AcrA

monomers.

Plasmid

pBAD33acrABhis was utilized to introduce disulfides between AcrA and AcrB. All
mutations were verified by using the sequencing method.
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4.2.3

Protein expression, SDS PAGE, and Western Blot Analysis

Plasmid containing the mutant protein with the correct sequence was transformed
by heat shock into E. coli knock out strains. The transformed cells were grown on LB agar
plate containing the proper antibiotic; (ampicillin-100 µg/ml, chloramphenicol -50 µg/ml)
at 37 degrees overnight. The colonies were cultured on 5 ml LB broth media supplemented
with ampicillin (100 µg /ml) in a shaker overnight. Next day, the cell was inoculated in a
100-fold dilution into a 5 ml fresh LB media supplemented with antibiotics. For samples
without AcrB, at OD600nm of 0.8-1.0, the culture was induced with arabinose to a final
concentration of 0.2% for two (2) hours, (samples with AcrB was induced overnight),
centrifuged at 3,500 revolution per minutes (rpm) for 3 minutes. Pellets was suspended
with 500 µl of Phosphate Buffer saline (PBS buffer recipe- Na2HPO4 - 0.0233%, NaH2PO4
– 0.2599%, NaCl – 300 mM & pH 7.9) and freshly prepared 20 mM iodoacetamide (IAM)
was added to the sample. Cell was lysed by a sonicator and then centrifuge at 1,400 rpm
for 5 minutes. The pellet was resuspended in 500 µl PBS and 20 mM IAM with 1% TritonX and shaken at medium speed to extract the protein. Cells were centrifuged at 1,400 rpm
for 5 minutes and the supernatant was retained. 6x SDS loading dye supplemented with
beta mercaptoethanol (BME) to a final concentration of 2% was added to some of the
samples and reduction was allowed for 30 minutes to test the effect of reducing agent on
oligomerization and disulfide bond formation. Samples was used to run sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) at 200 V for 40 minutes on a 12%
SDS gel and then was transferred and blotted on polyvinylidine difluoride membrane
(Millipore) in methanol for 30 minutes for 60 V at constant current of 350 mA. Protein was
detected with anti AcrA and AcrB antibody and visualized using standard methods. To

64

circumvent the possibility of free cysteine oxidation during the experimental procedure,
which will show false disulfide yield, IAM a thiol modifier was added to the buffers
throughout the experiment

143

. IAM can interact with membrane protein by entering the

hydrophobic core of a protein 168.
4.2.4

Drug Susceptibility Test

The minimum inhibitory concentration (MIC) was determined for erythromycin,
novobiocin, ethidium bromide (EtBr), rhodamine 6G (R6G), nalidixic acid (NAL), and
tetraphenylphosphonium chloride (TPP) following the CLSI guidelines142. Briefly,
overnight cultures of the indicated strain were diluted to a final concentration of 105
CFU/mL in fresh Muller Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St.
Louis, MO, USA) in a 48 well microtiter plate containing the indicated compounds at twofold serial dilutions. Plates were incubated at 370C with shaking at 160 rpm for 17 h; the
absorbance at 600 nm (OD600) were measured to identify the lowest concentrations with
no observable cell growth. All experiments were repeated at least three times.
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4.3

Results

4.3.1

Disulfide bond formed in AcrA113C/A155C does not depend on AcrB or
TolC

Figure 4.1 Probing the structure of AcrA oligomer using disulfide bond. A. CA trace
showing the structure of the AcrA hexamer when bound with AcrB. Subunits of
AcrA are color coded. The periplasmic domain of the AcrB trimer is also shown and
colored grey. The locations of the A155C/A113C pair and the R69C/L194C pair at
the interface of the blue and red subunits are highlighted using spheres. B. SDSPAGE analysis of cell lysate of RAM1418∆acrA expressing AcrAA155C/A113C. Several
high molecular weight band could be observed (lane 2), which disappeared after
reduction using BME (lane 1). C. Western blot analysis of cell lysate prepared from
RAM1418∆acrA (1, 2), MG1655∆acrAB (3, 4), and MG1655∆acrABTolC (5, 6)
expressing AcrAA155C/A113C, with (2, 4, 6) or without (1, 3, 5) reduction. In B and C,
the black arrows on the right marked the location of molecular weight markers. From
top to bottom, the bands correlate to 245, 190, 135, 100, 80 (red), 58, 46, 32, and 25
(green) kDa. The three gray arrows on the left marked the location of the monomer,
trimer, and hexamer bands.
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4.3.2

Disulfide bond formed in AcrR69C/L194C does not depend on AcrB or TolC

Figure 4.2 Formation of disulfide bond between R69C/L194C depend on the presence of
AcrB. A. Anti-AcrA Western blot analysis of AcrAR69C/L194C expressed in
RAM1418∆acrA, with (lane 1) or without (lane 2) reduction. B. Anti-AcrA Western blot
analysis of AcrAR69C/L194C co-expressed with AcrB in RAM1418∆acrA, with (lane 1) or
without (lane 2) reduction. C. Anti-AcrB Western blot analysis of AcrAR69C/L194C coexpressed with AcrB in RAM1418∆acrA, with (lane 1) or without (lane 2) reduction. D.
Anti-TolC Western blot analysis of AcrAR69C/L194C co-expressed with TolC in
RAM1418∆acrA, without (lane 1) or with (lane 2) reduction. The black arrows on the left
marked the location of molecular weight markers. From top to bottom, the bands correlate
to 245, 190, 135, 100, 80 (red), 58, 46, 32, and 25 (green) kDa.
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4.3.3

Introducing cysteine pairs at interaction interfaces of AcrA and AcrB

Figure 4.3 Crosslinking at the AcrA-AcrB interface. A. CA trace showing the structure of
the AcrA hexamer with bound AcrB. Subunits of AcrA are color coded. The periplasmic
domain of the AcrB trimer is also shown and colored grey except for the subunit interacting
with the blue and yellow AcrA subunit, for which the ribbon diagram is shown in purple.
The locations of the four cys pairs were highlighted in red spheres and labeled using fonts
that matches the color of the structure. B. Anti-AcrB Western blot analysis of samples
prepared from MG1655∆acrAB expressing AcrAR59C-AcrBG257C (lanes 1 and 2), AcrAP57CAcrBN191C (lanes 3 and 4), AcrAQ269C-AcrBQ197C (lanes 5 and 6), and AcrAT217C-AcrBS258C
(lanes 7 and 8), with (1, 3, 5, 7) or without (Lanes 2, 4, 6, 8) reduction. C. Anti-AcrA
Western blot analysis of the same set of samples. Grey arrows marked the location for
AcrB, AcrA, and a AcrA-AcrB complex, potentially (AcrA) 2AcrB based on the molecular
weight. In B and C, the black arrows on the right marked the location of molecular weight
markers. From top to bottom, the bands correlate to 245, 190, 135, 100, 80 (red), 58, and
46 kDa.
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Table 4.1 Drug Susceptibilities of AcrA mutants at the Inter subunit Interface
Mutants
Ram1418∆acrA
No plasmid
pBAD18AcrA
pBAD18AcrA
A113C/A155C
pBAD18AcrA A113C
pBAD18AcrA A155C
pBAD18AcrA R69C/L194C
pBAD18AcrA R69C
pBAD18AcrA L194C

MIC (µg/ml)
ERY
TPP
4
16
64
512
32
64

NOV
4
64
32
64
64
64
64
64

32
32
32
32
8

128
64
64
64
64

R6G
32
512
64
64
64
64
128
64

Table 4.2. Drug Susceptibilities of mutants at the interfaces of AcrA and AcrB
Mutants
MG1655∆acrAB
No plasmid
pBAD33 AcrAB
pBAD33 AcrA P57C-AcrB
N191C
pBAD33 AcrA P57C AcrB
pBAD33 AcrA AcrB N191C
pBAD33 AcrA Q269C-AcrB
Q197C
pBAD33 AcrA Q269C AcrB
pBAD33 AcrA AcrBQ197C
pBAD33 AcrA R59C-AcrB
G257C
pBAD33 AcrA R59C AcrB
pBAD33 AcrA G257C AcrB
pBAD33 AcrA T217C-AcrB
S258C
pBAD33 AcrA T217C AcrB
pBAD33 AcrA AcrB S258C

MIC (µg/ml)
ERY
TPP
8
16
128
512
64
256

NOV
8
128
64

R6G
32
1024
512

128
128
64

64
64
32

512
512
512

512
512
512

128
128
64

64
64
32

512
512
512

512
1024
256

128
128
128

64
64
64

512
512
512

512
512
512

128
128

64
32

512
256

512
512
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4.4

Discussion
The rationale behind using disulfide bond as a probe to study protein function stems

from the fact that formation of disulfide bond has the potential to improve the stability
of a protein or protein complex, but at the same time restrict local movement of related
residues

167

. While increase in stability could be beneficial to the activity of a protein

complex, restriction of conformational change could be detrimental to protein function.
Based on the tip-to-tip model of the efflux pump complex, residues were created at
the interface of helical hairpin of neighboring AcrA monomer (AcrA A113C-A155C
and AcrA R69C-L194C) and at AcrA-AcrB interface: AcrA beta-barrel domain - AcrB
DN subdomain (AcrA R59C-AcrB G257C and AcrA P57C-AcrBN191C,), AcrA lipoyl
domain - AcrB DN subdomain (AcrAQ267C-AcrB Q197C and AcrA T217C-AcrB
S258C).
We speculate that formation of inter molecular disulfide links between AcrA and
AcrB, and between neighboring AcrA subunits, would indicate that the tip-to-tip model
truly reflect the assembled structure of the complex in bacteria cells. This is important
since most supporting evidence for the tip-to-tip model comes from cryo-EM studies
using purified proteins. These residues chosen in this study were too far apart for
disulfide bond to form according to the deep interpenetration model. We showed that
the formation of disulfide bond at AcrA A113C-A155C and R69C-L194C does not
depend on AcrB or TolC in the E. coli genome, as seen from the western blot expression
tests. Formation of trimer, hexamer, and higher order oligomer in the double mutant,
supports previous claim that AcrA exist as trimers 150, 169.
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Additionally, we tested the function of the mutants using the drug susceptibility test.
The function of AcrA A113C-A155C was reduced with respect to novobiocin. It may
also be because the alpha helical hairpin domains of AcrA are very flexible 145, showing
a wide range of motion and capable of interdomain contacts. Thus, introducing double
cysteines at alpha helical hairpin interface, is likely to stabilize the interface and induce
conformational changes. At the AcrA-AcrB interface, only AcrA T217C-AcrB S258C
construct showed same activity as the wild type. This may be that conformational
change in this region is not linked to function. If locking and inhibiting protein
movement due to disulfide bond does not have any effect on function, possibly change
in protein conformation is not a requirement for function 170. The other AcrAB mutants
showed a reduced activity mostly in two-fold, probably because DN subdomains of
AcrB which is the N-terminal end of the TolC docking domain, naturally stabilize
interactions with TolC during complex assembly 56, 171 but has lesser affinity for AcrA.
Moreover, the lipoyl and beta barrel domains are very rigid 139, hence disulfide bond at
the interface with the DN subdomain of AcrB is not likely to have a profound effect on
protein stability or function.
The interaction interfaces of AcrA and AcrB could be potential targets of inhibitors
in a bid to lower the function of efflux pumps

172, 173

. These interfaces are properly

resolved in the cryo-EM structures of the full pump complex from which the tip-to tip
model, which is the basis of this study is derived 53. As a result, efflux pump inhibitors
(EPIs) such as DA-13-1809 and MBX2319 which can potentially block the tripartite
pump assembly, are being touted as potentiators of the activities of antibiotics, to
combat the spread of antibiotics resistance 174, 175.
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Table 4.3 Primers used in this study
Primers
AcrA A113C-F
AcrA A113C-R
AcrA A155C-F
AcrA A155C-R
AcrA R69C-F
AcrA R69C-R
AcrA L194C-F
AcrA L194C-R
AcrA P57C -F
AcrA P57C-R
AcrB N191C-F
AcrB N191C-R
AcrA Q269C-F
AcrA Q269C-R
AcrB Q197C-F
AcrB Q197C-R
AcrA R59C-F
AcrA R59C-R
AcrB G257C-F
AcrB G257C-R
AcrA T217C-F
AcrA T217C-R
AcrB S258C-F
AcrB S258C-R

Sequence (5’-3’)
CAGTGCGAAAGGTGATCTGTGTAAAGCCCAGGCTGCAGCC
GGCTGCAGCCTGGGCTTTACACAGATCACCTTTCGCACTG
CTGATGCGCAACAGGCGAATTGTGCGGTAACTGCGGCGAAAG
CTTTCGCCGCAGTTACCGCACAATTCGCCTGTTGCGCATCAG
CGGATCGCAGAAGTTTGTCCTCAAGTTAGCGGG
CCCGCTAACTTGAGGACAAACTTGTGCGATCCG
GTGACGGAAGGCGCATGTGTACAGAACGGTCAGGCG
CGCCTGACCGTTCTGTACACATGCGCCTTCCGTCAC
CAGATCACAACCGAGCTTTGTGGTCGCACCAGTGCCTAC
GTAGGCACTGGTGCGACCACAAAGCTCGGTTGTGATCTG
CGTATCTGGATGAACCCGTGTGAGCTGAACAAATTCCAG
CTGGAATTTGTTCAGCTCACACGGGTTCATCCAGATACG
GACGTTACCGTTGATTGTACCACTGGGTCTATC
GATAGACCCAGTGGTACAATCAACGGTAACGTC
GAGCTGAACAAATTCTGTCTAACGCCGGTTGATGTC
GACATCAACCGGCGTTAGACAGAATTTGTTCAGCTC
CAGATCACAACCGAGCTTCCGGGTTGTACCAGTGCCTACCGGATC
GATCCGGTAGGCACTGGTACAACCCGGAAGCTCGGTTGTGATCTG
CTGAAAGTGAATCAGGATTGTTCCCGCGTGCTGCTGCGTGAC
GTCACGCAGCAGCACGCGGGAACAATCCTGATTCACTTTCAG
CCGATCTACGTTGATGTGTGTCAGTCCAGCAACGACTTC
GAAGTCGTTGCTGGACTGACACACATCAACGTAGATCGG
CTGAAAGTGAATCAGGATGGTTGTCGCGTGCTGCTGCGTTCC
GGAACGCAGCAGCACGCGACAACCATCCTGATTCACTTTCAG
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CHAPTER 5. DISCUSSION AND FUTURE DIRECTION
Bacteria resistance is a major global threat to the treatment of infections. Many
bacteria have become ‘immune’ to treatment with drugs, some even developing ability to
ward off several class of drugs, thereby becoming superbugs, a term coined as multi drug
resistance pathogens. Efflux pumps have been implicated as causes of this observed
phenomenon. RND pump especially AcrAB-TolC has been the subject of intense scrutiny
and scientific study over the years. The crystallographic determination of the individual
components and the recent cryo-EM structure of the entire system have provided
tremendous insight into the assembly process and mechanism of action of the pump.
However, there are still questions left to be answered. For the projects in this study, the
aim was to explore the periplasmic adaptor protein AcrA. We studied its role in the
assembly process of AcrAB, the functional relevance of the unstructured region, and the
dynamics of the protein using disulfide trapping method.

Understanding the assembly process of AcrAB-TolC in vitro has been hampered by
the very transient nature of the intermediate stages. We set out to decipher this assembly
process by utilizing the phenomena called ‘dominant negative’ effect. This relies on the
notion that if we incorporate an overexpressed and defective AcrA mutant into the pump,
the assembly will be disrupted and hence the efflux efficiency will reduce. We expect that
the mutants will out-compete its lesser expressed genomic counterpart to bind to genomic
AcrB, and thus dominate the phenotype of the pump. We examined different mutants
defective in different aspects of AcrA like the interaction site with TolC, AcrA assembly,
site that affects AcrA conformation, and AcrA in anchor free strain. We did not notice any
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dominant negative effect leading us to conclude that the complex has a very efficient proofread mechanism that prevents the formation of a futile complex. Our data suggests that the
AcrAB complex is very tight in that once it is formed, it is difficult for it to dissociate into
its components. This precludes any interaction with the defective mutants. We used MIC
and western blot expression tests for these experiments. Nevertheless, it may be interesting
to use other methods to probe this phenomenon. Using a fluorescent sensitive method like
studying how the pump effluxes Nile red or ethidium bromide when the defective mutants
are incorporated may be one approach.

For the second project, we studied the functional relevance of the unstructured part of
AcrA. The crystal structure of AcrA excludes at the N-terminal end, the first thirty-seven
(37) amino acids and at the C terminal end amino acid residues 375-397. We created several
mutations on both ends and used MICs to determine its effects on the function of AcrA.
Our data showed that the shortening of the protein length at the N terminus drastically
reduced the function of the protein. This function was restored when the membrane anchor
was removed, as the signal peptide of AcrA was replaced with that of OmpA. We found
that at least part of the sequence is still needed, with the removal of residues 26-37 resulting
in a significant loss of AcrA activity. To establish the potential role of the unresolved Cterminal sequence, we constructed a series of truncation mutations in which the C-terminal
residues of AcrA was systematically removed via introduction of stop codons. Result
suggested that the 20-residue flexible C-terminal tail is dispensable and not important for
activity, but residues before Q376 are critical for AcrA activity. We also found that AcrA
fusion constructs retained the ability to interact with AcrB as revealed by the retention of
efflux function. The introduction of an inactive mutant R128D and A155D into the AcrA74

AcrAΔ1-25 also shows efflux efficient pump. Efflux active fusion constructs points to the
1:1:1 ratio, as an inactive pair should not interfere with function. Potential Inactivity of
constructs would have supported the 1:2:1 ratio implying that AcrA monomers must be
active for efflux function to be retained. However, it is difficult to conclude either way due
to cleavage of the oligomers to monomers which could contribute to the observed activity.
Future direction will be to create a mutation that will preclude cleavage of the oligomer,
such as AcrA fusion that deletes residues 378-381, as valine is present at position 378, as
the periplasmic protease Deg P cleaves peptide bonds between hydrophobic residues at
Val-Xaa and Ile-Xaa.
The third aspect of this work involved probing the dynamics of AcrA and its
interaction sites with AcrB using disulfide bonds. We chose sites using the DbD 2.0
software based on proximity of sites according to the ‘tip-to-tip’ model of the pump
assembly. Our data revealed that disulfide bond at AcrA inter subunit interface did not
rely on the presence of AcrB. Those formed between AcrA β barrel domain-AcrB DN
subdomain and between AcrA lipoyl domain-AcrB DN subdomain affected protein
function to different degrees. T217C-AcrB S258C construct showed same or almost same
activity as the wild type. We speculate that conformational change in this region may not
be efflux relevant. We used BME as a reducing agent to show that the higher oligomers
resulted from disulfide bond formation. However, we did not find any disulfide bond that
could be linked to efflux and/or assembly. Future direction will include probing more
positions in the protein for assembly and functionally relevant disulfide bonds. This will
provide novel and better comprehension of the AcrAB-TolC dynamics.
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